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Spinal muscular atrophy (SMA) is caused by deletions or mutations of the Survival Motor Neuron 1 (SMN1)
gene coupled with predominant skipping of SMN2 exon 7. The only approved SMA treatment is an antisense
oligonucleotide that targets the intronic splicing silencer N1 (ISS-N1), located downstream of the 5′ splice
site (5′ss) of exon 7. Here, we describe a novel approach to exon 7 splicing modulation through activation of a
cryptic 5′ss (Cr1). We discovered the activation of Cr1 in transcripts derived from SMN1 that carries a
pathogenic G-to-C mutation at the first position (G1C) of intron 7. We show that Cr1-activating engineered
U1 snRNAs (eU1s) have the unique ability to reprogram pre-mRNA splicing and restore exon 7 inclusion in
SMN1 carrying a broad spectrum of pathogenic mutations at both the 3′ss and 5′ss of the exon 7. Employing a
splicing-coupled translation reporter, we demonstrate that mRNAs generated by an eU1-induced activation of
Cr1 produce full-length SMN. Our findings underscore a wider role for U1 snRNP in splicing regulation and
reveal a novel approach for the restoration of SMN exon 7 inclusion for a potential therapy of SMA.
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ABSTRACT
Spinal muscular atrophy (SMA) is caused by dele-
tions or mutations of the Survival Motor Neuron 1
(SMN1) gene coupled with predominant skipping of
SMN2 exon 7. The only approved SMA treatment is
an antisense oligonucleotide that targets the intronic
splicing silencer N1 (ISS-N1), located downstream
of the 5′ splice site (5′ss) of exon 7. Here, we de-
scribe a novel approach to exon 7 splicing modula-
tion through activation of a cryptic 5′ss (Cr1). We dis-
covered the activation of Cr1 in transcripts derived
from SMN1 that carries a pathogenic G-to-C mutation
at the first position (G1C) of intron 7. We show that
Cr1-activating engineered U1 snRNAs (eU1s) have
the unique ability to reprogram pre-mRNA splicing
and restore exon 7 inclusion in SMN1 carrying a
broad spectrum of pathogenic mutations at both the
3′ss and 5′ss of the exon 7. Employing a splicing-
coupled translation reporter, we demonstrate that
mRNAs generated by an eU1-induced activation of
Cr1 produce full-length SMN. Our findings under-
score a wider role for U1 snRNP in splicing regu-
lation and reveal a novel approach for the restoration
of SMN exon 7 inclusion for a potential therapy of
SMA.
INTRODUCTION
Alternative pre-mRNA splicing enhances the coding po-
tential of the eukaryotic genome by enabling single genes
to produce multiple transcripts/proteins through removal
of intronic sequences in different combinations (1). A vast
majority of human introns belong to the GUAG type in
which the 5′ splice site (5′ss) and the 3′ss are defined by
GU and AG dinucleotides at the first and last two posi-
tions, respectively (2). In addition, pre-mRNAs harbor a
significantly higher number of cryptic splice sites that re-
semble canonical GUAG type splice sites but are usually
suppressed under normal conditions (3). Exon and intron
definition models, which are mutually exclusive, are the two
primary mechanisms proposed for the selection of splice
sites (4,5). These simplistic models do not fully encompass
the complexity of splicing regulation that is influenced by
both transcription and the overall context of the splice site
(6,7). Even more puzzling is the mechanism of suppression
of cryptic splice sites that generally overlap with silencer ele-
ments (8,9). Diverse factors, including hnRNP C, TDP-43,
PTBP1 and PTBP2, have been implicated in the genome-
wide suppression of cryptic splice sites (10–12). Point mu-
tations leading to the activation of cryptic splice sites have
been associated with various pathological conditions (13).
Activation of cryptic splice sites often generates transcripts
harboring premature termination codons (PTCs) leading
to their degradation by nonsense-mediated decay (NMD)
(13). Therefore, the level of transcripts generated by the ac-
tivation of cryptic splice sites cannot be accurately deter-
mined. However, usage of a cryptic splice site downstream
of a stop codon or at a site that retains the open-reading
frame (ORF) is likely to generate stable transcripts. A re-
cent study attempted to uncover rules why certain pointmu-
tations favor activation of a cryptic 5′ss instead of an exon
skipping (14). However, there is no systematic study on tar-
geted activation of a cryptic 5′ss that prevents exon skipping
caused by a pathogenic mutation at the splice site.
Splicing is catalyzed by the spliceosome, a macromolecu-
lar machine in which five small ribonucleoproteins (U1, U2,
U4, U5 andU6 snRNPs) play an indispensable role (15,16).
Spliceosomal assembly begins with the recruitment of U1
snRNP, which is expressed at much higher levels than other
snRNPs in human cells (17). During pre-mRNA splicing,
U1 snRNPs are recruited at more sites than are actually uti-
lized (18). Recruitment of U1 snRNP at multiple sites on
pre-mRNA offers several benefits, such as suppression of
cryptic exons, maintenance of mRNA length and provision
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of directionality to transcription (19–22). In specific cases
when U1 snRNP activates the usage of a 5′ss away from
its annealing position, it is referred to as a shift-U1 snRNP
(23). Consistently, it has been shown that engineered U1
snRNAs (eU1s) that anneal to different intronic sequences
could promote the usage of the upstream 5′ss (24–26). How-
ever, proof of the principle that an eU1 could activate a
‘desired’ cryptic 5′ss and neutralize the consequences of a
pathogenic mutation at the native 5′ss of an exon remains
to be demonstrated.
Humans possess two almost identical copies of the Sur-
vival Motor Neuron gene, SMN1 and SMN2 (27). SMN1
predominantly produces full-length SMN, an essential pro-
tein involved in snRNP biogenesis, transcription, transla-
tion, cell signaling, macromolecular transport and stress
granule formation (28). Due to overwhelming skipping
of exon 7, SMN2 mostly produces the truncated protein
SMN7 (29,30). The 54 nucleotide (nt)-long exon 7 codes
for the last 16 amino acids that play a critical role in SMN
stability (31). Low levels of SMN due to deletions or mu-
tations of SMN1 leads to spinal muscular atrophy (SMA),
one of the leading genetic causes of infant mortality (32).
Due to the notion that re-direction of SMN2 exon 7 dur-
ing pre-mRNA splicing holds the answer for the treatment
of most SMA patients, the mechanism of exon 7 splicing
regulation has been intensively investigated (33,34). Early
studies revealed that skipping of SMN2 exon 7 is triggered
by a C-to-T substitution at the 6th position (C6U substitu-
tion in RNA) of exon 7 (29,35). Subsequent studies showed
that the poor recruitment of U1 snRNP at the 5′ss of exon
7 is also a limiting factor for SMN2 exon 7 inclusion (36–
38). In particular, we demonstrated that the intronic splic-
ing silencer N1 (ISS-N1) located downstream of the 5′ss of
exon 7 plays a critical role in inducing the skipping ofSMN2
exon 7 [Figure 1A, (39)]. Various independent pre-clinical
and clinical studies confirmed unparalleled therapeutic ben-
efits of ISS-N1-targeting antisense oligonucleotides (ASOs)
(40). The FDA has recently approved nusinersen, an ISS-
N1-targeting ASO, as the first medical therapy for SMA
(41). Nusinersen is also the first antisense drug that restores
the complete ORF of a gene via splicing modulation (42).
In parallel with the advancements made on the therapeu-
tic front, there has been continued progress towards our un-
derstanding of the mechanism by which ISS-N1 and other
regulatory elements modulate SMN2 exon 7 splicing. ISS-
N1 harbors two adjacent motifs associated with the neg-
ative regulator(s) hnRNP A1/A2 and is followed by two
uridine-rich clusters (URC1 andURC2) associated with the
positive regulator(s) TIA1/TIAR [Figure 1A, (43,44)]. We
recently showed that TIA1 is a gender-specific disease mod-
ifier in a mouse model of SMA (45). The 5′ end of ISS-N1
partially overlaps with an 8-nt long GC-rich sequence, se-
questration of which by an 8-mer ASO fully restores SMN2
exon 7 inclusion and provides therapeutic benefits in mouse
models of SMA [Figure 1A, (46,47)]. In addition, the first
residue of ISS-N1 strengthens a unique structure formed
by long-distance interactions involving ISS-N2, a deep in-
tronic inhibitory element [Figure 1A, (48)]. ASO-mediated
sequestration of ISS-N2 has been recently shown to pro-
duce a gender-specific amelioration of the phenotype in a
mild SMA mouse model (49). There have also been studies
on eU1s that promote SMN2 exon 7 inclusion by targeting
ISS-N1 or a nearby region (25,26). Sequences downstream
of the 5′ss of exon 7 harbor several GU dinucleotides; how-
ever, it is not known if any of these dinucleotides is part of a
putative cryptic 5′ss. Considering that the stop codon is lo-
cated within exon 7, transcripts generated by the activation
of a cryptic 5′ss downstream of exon 7 may escape NMD.
Hence, activation of such a cryptic 5′ss would offer a novel
therapeutic avenue for patients carrying deadlymutations at
the wild type 5′ss (wt-5′ss). Currently, there is no evidence
that a ‘functional’ cryptic 5′ss exists downstream of exon 7,
let alone that it could be activated under normal or patho-
logical condition even by the reported eU1s that target ISS-
N1 or nearby sequences.
Here, we describe two novel cryptic 5′ss, Cr1 and Cr2, lo-
cated 23 and 51 nts downstream of the wt-5′ss of SMN exon
7, respectively. The surprising discovery of Cr1 and Cr2 was
possible due to the employment of the SMN1G1C minigene
that harbors a recently reported dead-end G1C mutation
at the first position of intron 7 of SMN1. The G1C mu-
tation was first discovered in a patient that displayed a se-
vere SMA phenotype and died at ∼4 months of age (50).
This patient had only a single copy of SMN2 in addition
to carrying the G1C mutation in SMN1 (50). Reproduc-
ing the lethal effect of G1C, the SMN1G1C minigene showed
complete skipping of exon 7. In order to suppress skipping
of SMN1G1C exon 7, we screened a library of eU1s that
targeted the G1C-5′ss. While most eU1s suppressed exon
7 skipping, they also activated Cr1 and Cr2. Interestingly,
Cr1, which partially overlaps with ISS-N1, emerged as the
most favorable cryptic 5′ss induced by eU1 overexpression.
Our results reveal that ISS-N1 is a suppressor of theCr1 site.
We show strong activation of Cr1 by eU1s targeting both
upstream and downstream sequences. Further, we demon-
strate that the U1 snRNP-based approach could potentially
be employed to restore exon 7 inclusion from SMN1 carry-
ing a variety of pathogenic mutations at both the 3′ and 5′ss
of exon 7. Finally, we show that mRNAs generated by an
eU1-induced activation of Cr1 can be translated into full-
length SMN. Our findings suggest an expanded role of U1
snRNA in splicing regulation and uncover a novel therapeu-
tic strategy applicable to a broad spectrumof SMApatients.
MATERIALS AND METHODS
Cell cultures, siRNAs and ASOs
All tissue culture media and supplements were purchased
from Life Technologies. HeLa cells and human neuroblas-
toma SH-SY5Y cells were obtained from American Type
Culture Collection.Mousemotor-neuron-like NSC-34 cells
were generously provided by Dr. N. Cashman (51). HeLa
and NSC-34 cells were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM). SH-SY5Y cells were maintained
in 1:1 mixture of Minimum Essential Medium (MEM) and
F12 Medium. Both media were supplemented with 10% fe-
tal bovine serum.
Small interfering RNAs (siRNAs, ON-TARGETplus
SMARTpool) against hnRNPA1 and A2B1 and antisense
oligonucleotides (ASOs) used in this study were purchased
from Dharmacon Inc. An ON-TARGETplus nontargeting
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Figure 1. Effect of eU1 base pairing with G1C-5′ss on splicing of exon 7 in SMN1G1C transcripts. (A) Diagrammatic representation of splicing regulatory
elements. Exonic and intronic sequences are shown in capital and lower-case letters, respectively. Numbering starts from the first position of intron 7. The
GU dinucleotides are indicated in red. Positive (+) and negative (–) regulatory elements of exon 7 splicing are highlighted in colored boxes (also see refs.
39,43,44,46,48). Cryptic 5′ss within intron 7 and exon 6 are indicated by arrows. Abbreviations: Cr1, cryptic site 1; Cr2, cryptic site 2; E6Cr, cryptic site
within exon 6. (B) Diagrammatic representation of base pairing formed between eU1s and G1C-5′ss of exon 7. Left panel depicts eU1-M1C-11 that forms
the maximum possible 11 base pairs with the G1C-5′ss. The remaining eU1s form progressively decreasing numbers of continuous base pairs with G1C-5′ss
(right panel). Number of hydrogen bonds for each U1 construct is shown. Mutated nucleotides within U1 snRNAs are indicated in green. Base pairing
is marked by black dots; red dots represent a wobble base pair. G1C mutation at the 5′ss of exon 7 is shown in blue. The 3′ss and 5′ss are indicated by
arrows. Abbreviations: HB, hydrogen bonds; wt, wild type. (C) In vivo splicing pattern of transcripts generated by SMN1G1C minigene in the presence of the
overexpressed eU1s shown in (B). The identity of eU1 constructs is marked at the top of the gel. The splice products are indicated on the left and the right of
the gel. Quantification of the relative amount of the indicated splice products is given in the bottom panel as a bar diagram. Error bars represent standard
error. Abbreviations: C, control when SMN1G1C minigene was transfected without a U1 construct. Other abbreviations are described in Supplementary
Table S1.
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pool was used as a negative siRNA control. The ASOs in-
corporated a phosphorothioate backbone and 2′-O-methyl
modifications at each base.
Generation of SMN minigenes
The minigenes pSMN1I6 and pSMN2I6 were de-
scribed previously (52). Here we refer to pSMN1I6 and
pSMN2I6 as SMN1 and SMN2, respectively. Minigenes
with site-specific mutations, SMA-patient-associated muta-
tions and the insertion of the neutral Sequence 1 and Se-
quence 2 were generated similarly as described in (52) us-
ing a two-step high-fidelity PCR with Phusion DNA poly-
merase and SMN1/SMN2 as a template. The identities
of the newly constructed minigenes were confirmed by se-
quencing. All primers used were purchased from Integrated
DNATechnologies (IDT). Their sequence informationmay
be obtained upon request. Reagents for PCR and cloning
were purchased from New England Biolabs.
Generation of U1 snRNA constructs
Plasmids pUCBU1 and pUCBU1 were generous gifts
fromDr.H. Schaal (53). Site-specificmutations at the 5′ end
of U1 RNA were introduced by high-fidelity PCR as de-
scribed in (38). The identity of all newly generated U1 con-
structs was confirmed by sequencing. All primers used were
purchased from IDT. Their sequence information could be
obtained upon request.
Cell transfections
Transient transfections of cells were performed using either
X-tremeGene HP (Roche Life Science) or Lipofectamine
2000 (Life Technologies), following the manufacturer’s rec-
ommendations. Briefly, to study the effect of eU1s on splic-
ing of minigene exon 7, pre-plated cells were co-transfected
with 0.05 g of the SMN minigene of interest and a given
U1 snRNA construct (0.05 g) using 1 l of X-tremeGene
HP reagent. The total amount of plasmid DNA was main-
tained constant (0.5 g) using an empty vector (pCI or pCI
neo). In the case of Lipofectamine 2000, the total amount
of plasmid DNA was maintained at 0.8 g and 2 l of the
transfection reagent were used. To study the effect of eU1s
on splicing of endogenous exon 7, HeLa cells were trans-
fectedwith 0.5g of a givenU1 snRNAconstruct using 1l
of X-tremeGene HP reagent. Transfections were performed
in 24-well plates. Twenty-four hours after transfections, cells
were washed with ice-cold phosphate-buffered saline (PBS,
Life Technologies) and lysed in TRIzol reagent (Life Tech-
nologies) directly in eachwell. To test the ability of eU1 snR-
NAs to promote the full-length SMN protein production
from the expression vector FLAG-SMN1G1C, HeLa cells
were reverse transfected with FLAG-SMN1G1C (0.5 g)
and a U1 snRNA construct of interest (1.0 g), using Lipo-
fectamine 2000. The FLAG-SMN1 plasmid was used as a
control. The total amount of DNA in each transfection re-
action was maintained constant (2.0 g) by adding pCI neo
vector. For each transfection, DNA–Lipofectamine 2000
complex was prepared following the manufacturer’s recom-
mendations, and combined with HeLa cell suspensions in a
total volume of 2 ml. These cells were then plated in six-well
plates, 2 ml per one well. Cells were collected formaking cell
lysates and total RNA preparation 24 h later. Experimental
results were confirmed by at least two independent experi-
ments.
Endogenous U1 snRNA inactivation
To test the effect of inactivation of endogenous U1 snRNA
on the ability of eU1-I7R7 to promote exon 7 inclusion,
pre-plated HeLa cells were co-transfected with 0.05 g of
a minigene of interest, 0.05 g of an empty vector (pCI) or
eU1-I7R7 and 200 nM of either wtU1 ASO or the control
oligonucleotide (5′-UUGCCUUUCU-3′; 54) using 2 l of
Lipofectamine 2000. To test the effect of endogenous U1
snRNA inactivation on the ability of F14 ASO (48,54) to
promote exon 7 inclusion, pre-plated HeLa cells were co-
transfected with 0.05 g of a minigene of interest, 50 nM
of F14 alone or with 200 nM of wtU1 ASO using 2 l
of Lipofectamine 2000. In all transfection reactions, total
amount of nucleic acids was maintained constant (0.8 g)
using the control oligonucleotide. HeLa cells were seeded in
24-well plates (∼0.6 × 105 cells per well) 38 h prior to co-
transfections and collected 22–24 h after co-transfections
took place using TRIzol reagent. Results were confirmed
by at least two independent experiments.
hnRNP A1/A2 depletion
hnRNPA1 and hnRNPA2B1were knocked down simulta-
neously using siRNAs (ON-TARGETplus SMART pool).
To do so, HeLa cells were reverse transfected with siRNAs
twice with an interval of ∼48 h. For each siRNA transfec-
tion, an siRNA-Lipofectamine 2000 complex was prepared
following the manufacturer’s recommendations, and com-
bined with HeLa cell suspensions in a total volume of 2 ml.
These cells were then plated in six-well plates, 2 ml per one
well. For the first transfection, the final concentration for
the control siRNA was 50 nM and for the siRNAs against
hnRNP A1 and A2B1 it was 25 nM each. The next day, the
transfected HeLa cells were trypsinized and moved to 60
mm dishes. The second reverse transfection of HeLa cells
with siRNAs was performed ∼48 h after the first one essen-
tially as described above, except that the siRNA concentra-
tion was decreased to 12 nM each for the siRNAs against
hnRNP A1 and A2B1. Twenty-six hours after the second
siRNA transfection,HeLa cells were trypsinized and seeded
in 6-well plates to be transfected with the minigenes of in-
terest the next day. The density of plating per well was ∼1.1
× 106 cells. HeLa cells were transfected∼24 h later with 0.2
g of a given minigene and the corresponding siRNAs (10
nM each for the siRNAs against hnRNP A1 and A2B1 and
25 nM for the control siRNA) using Lipofectamine 2000.
Cells were collected ∼24 h later; one third of the cells was
used for total RNA preparation and two-thirds for mak-
ing whole-cell extracts as previously described (55). Results
were confirmed by at least three independent experiments.
In vivo splicing
Total RNA was isolated from cells using TRIzol reagent
(Life Technologies), following the manufacturer’s recom-
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mendations. RNA was treated with RQ1 RNase-free
DNase (Promega) followed by phenol:chloroform (Om-
niPur) extraction and ethanol precipitation. Unless oth-
erwise stated, cDNA was generated using 0.5 or 0.8 g
of total RNA in a 5 l reaction, employing SuperScript
III Reverse Transcriptase (RTase, Life Technologies) and
oligo(dT)12–18 primer (Life Technologies). 0.8 l of RTase
reaction was then used as a template for PCR amplification
in a 10 l reaction. Amplification was carried out with Taq
DNA Polymerase (New England Biolabs) and the primer
pair P1 and P2 (36). Primer P2 was labeled at the 5′-end
with [ -32P] ATP (6000 Ci/mmol, Perkin-Elmer) using T4
PolynucleotideKinase (NewEngland Biolabs). For amplifi-
cation of endogenous SMN, PCR reactions were performed
using primers P31 and P25 orN-24 and P26 (44) in the pres-
ence of a trace amount of [-32P] dATP (3000 Ci/mmol,
Perkin Elmer), followed by phenol:chloroform extraction
and ethanol precipitation. To distinguish splice isoforms
that originated from SMN2 splicing, ethanol precipitated
PCR products were subjected to overnight DdeI digestion
as previously described (44).Multi-exon-skipping detection
assay (MESDA) was carried out as described previously
(55–58), using primers located in exon 1 and exon 8 of SMN
(56), where the reverse primer was labeled at the 5′-end with
[ -32P] ATP (6000 Ci/mmol, Perkin-Elmer). Splicing prod-
ucts were resolved on a 6% native polyacrylamide gel. Anal-
ysis and quantifications of splice products were performed
using a FPL-5000 Image Reader andMulti Gauge software
(Fuji Photo Film Inc). For amplification of splice products
generated from the FLAG-SMN1G1C and FLAG-SMN1
expression vectors, cDNA was generated using 1 g of to-
tal RNA in a 5 l reaction and splice products amplified by
PCR using primers located in 3XFLAG-tag region and the
beginning of exon 8. PCR products were separated on a 5%
native acrylamide gel and visualized by ethidium bromide
staining. Gel images were obtained using a UVP BioSpec-
trum AC Imaging System (UVP).
Identification of novel splice isoforms
Bands of interest corresponding to different splice isoforms
were excised from a 5% or a 6% native gel, and the DNA
was recovered using the ‘crush and soak’ method (44) fol-
lowed by ethanol precipitation. The recovered products
were then cloned in a pGEM-T easy vector (Promega) fol-
lowing the manufacturer’s recommendations. Recombinant
clones were identified by white/blue colony screening on
indicator plates. Several clones were randomly selected for
each splice variant. Clones were purified using the QIAprep
Spin Miniprep Kit (Qiagen) and sequenced.
Generation of SMN protein expression vectors
Human FLAG-SMN1 and FLAG-SMN1G1C expression
vectors were generated as follows. 3XFLAG-tagged SMN
cDNA sequence from exon 1 to exon 5 was ligated to the
sequence containing exon 6, exon 7, exon 8 and the inter-
vening intronic sequences using a multistep PCR approach
in which the 3XFLAG-SMN expression vector (58) and the
SMN1 /SMN1G1C minigenes served as templates. The final
PCR product was comprised of 3XFLAG tag followed by
an in-frame SMN cDNA sequence from exon 1 to exon 6
followed by a shortened version of intron 6 (52), the entire
exon 7, the entire intron 7 and 464 nucleotides of exon 8.
This PCR fragment was cloned into pCI expression vec-
tor digested with NotI and XhoI. The identity of FLAG-
SMN1 and FLAG-SMN1G1C constructs was confirmed by
sequencing.
Western blot analysis
In hnRNP A1/A2 depletion experiments whole-cell lysates
from HeLa cells were prepared using ice-cold radioim-
munoprecipitation assay (RIPA) buffer (Boston BioProd-
ucts) supplemented with Halt Protease Inhibitor Single-
Use cocktail (Thermo Scientific). Protein concentrations
were determined using the Bio-Rad protein assay (Bio-
Rad). Protein samples (15 g per lane) were resolved on
10% SDS-polyacrylamide gels, transferred to membranes
(Immun-Blot PVDF Membrane for Protein Blotting, Bio-
Rad) using the Transfer-Blot Turbo Transfer System (Bio-
Rad), and blocked with 5% nonfat milk prepared in Tris-
buffered saline containing 0.05% Tween-20 (TBST). Af-
ter incubation with primary antibodies, membranes were
rinsed in TBST at least three times (10 min each) and
incubated with the appropriate secondary antibody. The
following primary and secondary antibodies were used
for Western blot analysis: mouse monoclonal anti-hnRNP
A1 (1:5000), clone 9H10 (Abcam; ab5832), mouse mon-
oclonal anti-hnRNP A2B1 (1:1000), clone DP3B3 (Ab-
cam; ab6102), mouse monoclonal anti-GAPDH (1:4000),
clone 6C5 (Abcam; ab8245), rabbit polyclonal anti--actin
(1:2000, Sigma-Aldrich; A2103), mouse monoclonal anti-
-tubulin (1:4000, Sigma-Aldrich; T6199), goat anti-mouse
horseradish-peroxidase-conjugated antibody (1:4000, Jack-
son Immunoresearch; 115-035-003) and donkey anti-rabbit
horseradish-peroxidase-conjugated antibody (1:2000, GE
Healthcare; NA934V). Membranes were re-probed for pro-
teins of interest following stripping with Restore West-
ern Blot Stripping Buffer (Thermo Scientific). To ana-
lyze expression of the FLAG-tagged SMN proteins, HeLa
cells were harvested, and cell lysates prepared similarly as
previously described (39,44). One-eleventh of each lysate
was used for one blot. Protein samples were resolved on
14% SDS-polyacrylamide gels and transferred on PVDF
membranes (Immun-Blot PVDF Membrane for Protein
Blotting, Bio-Rad) using the Transfer-Blot Turbo Trans-
fer System (Bio-Rad). Membranes were blocked with 5%
nonfat milk prepared in TBST followed by incubation
with horseradish-peroxidase-conjugated anti-FLAG anti-
body (1:4000), clone M2 (Sigma-Aldrich). After visualiz-
ing the results, membranes were stripped and re-probed for
-actin using the primary and secondary antibodies listed
above. Proteins were visualized using Clarity Western ECL
Blotting substrate (Bio-Rad), or SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher Scientific).
Membranes were scanned using a UVP BioSpectrum AC
Imaging System (UVP). Results were confirmed by at least
two independent experiments.
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Computational analysis
The strength of the 5′ and 3′ splice sites was determined
usingMaxEntScan scoring algorithm (http://genes.mit.edu/
cgi-bin/Xmaxentscan scoreseq.pl) (59). The 5′ splice sites
were also scored using the HBond score web interface, ver-
sion 3.4 (http://www2.hhu.de/rna/html/hbond score.php).
CRYP-SKIP prediction algorithm was used to determine
whether a splicing mutation of interest would result in exon
skipping or activation of cryptic/di novo splice sites (60).
RESULTS
EngineeredU1 snRNAs (eU1s) suppress exon 7 skipping from
SMN1 carrying a lethal splice site mutation
To examine the effect of the lethal G1C mutation, we gen-
erated the SMN1G1C minigene, in which the G residue at
the first position of intron 7 of SMN1 is replaced with a
C. Reproducing the splicing pattern in patient tissues (50),
the SMN1G1C minigene showed complete skipping of exon
7 in different cell types includingHeLa, neuronal SH-SY5Y
and mouse motor neuron-like NSC34 cells (Supplementary
Figure S1). We conducted all subsequent studies in HeLa
cells. To test whether splicing of SMN1G1C exon 7 could
be modulated, we generated a library of eU1s predicted
to restore base pairing with the +1C position of intron 7
in addition to forming varying degree of complementar-
ity with the G1C-5′ss (Figure 1B). We then co-transfected
cells with the SMN1G1C minigene and each eU1 and de-
termined the splicing pattern of SMN1G1C exon 7 ∼24 h
post transfection. Overexpression of all eU1s that formed a
strong RNA:RNA duplex comprised of 19 or more hydro-
gen bonds with the G1C-5′ss substantially decreased exon 7
skipping and promoted intron 7 retention (Figure 1C). As
expected, wtU1 had no effect on splicing of SMN1G1C exon
7 (Figure 1C). Surprisingly, in the presence of eU1s we ob-
served three novel bands. Cloning and sequencing of these
bands confirmed the activation of two cryptic 5′ss (Cr1 and
Cr2) within intron 7 and one cryptic 5′ss (E6Cr) within
exon 6 (Figures 1A, C and Supplementary Figure S2). Of
note, most eU1s we employed had poor complementarity
with the cryptic sites (Supplementary Figure S3). Hence,
RNA:RNA duplexes formed by the eU1s at the G1C-5′ss
appeared to be the sole driving force behind the activa-
tion of these cryptic splice sites. While usage of the E6Cr
has been previously reported in hybrid SMN1/SMN2mini-
genes (18), Cr1 and Cr2 are novel sites, activation of which
will increase the size of exon 7 by 23 and 51 nucleotides (nts),
respectively (Figure 1A). Since the stop codon is located
within exon 7, usage of Cr1 or Cr2 will result in generation
of splice products that retain the ORF for the synthesis of
full-length SMN.
The Cr2 sequencemotif is closest to the consensus 5′ss se-
quence, since this site contains -1G, +5G and +6U residues.
Yet, Cr1 was used the most in SMN1G1Ctranscripts. To
better understand the mechanism of cryptic splice site se-
lection, we employed various algorithms to analyze the
strengths of all putative cryptic splice sites within the last
105 nts of intron 6, the entire exon 7, and the first 99 nts
of intron 7. We began our analysis with the CRYP-SKIP
prediction algorithm, which determines whether a splic-
ing mutation will result in exon skipping or activation of
a cryptic/di novo splice site (60). This algorithm uses a scale
of 0 to 1, with higher values indicating favorability for us-
age of the cryptic site. The analysis revealed the probability
of a cryptic splice site activation (PCR-E) versus exon 7 skip-
ping for SMN1 and SMN2 as 0.39 and 0.12, respectively.
CRYP-SKIP algorithm failed to predict activation of either
Cr1 or Cr2, while it predicted a cryptic 5′ss within exon 7
(GUdinucleotides at positions 30 and 31).We next analyzed
cryptic splice site strengths using MaxEntScan scoring al-
gorithm developed by Yeo and Burge (59). The algorithm
simultaneously analyses 9-mers, taking into account both
non-adjacent and adjacent dependencies between positions
within RNA regulatory sequences, such as the 5′ss. The wt-
5′ss of exon 7 was scored as the strongest followed by E6Cr,
then Cr2 and finally Cr1 (Supplementary Table S2). Since
MaxEntScan also failed to predict Cr1 as a strong site, we
infer several factors in addition to base pairing with the U1
snRNP contribute towards the favored selection of Cr1.
Intron 7 retention was the major splicing event in the
presence of the G1C-5′ss-targeting eU1s. We observed an
inverse correlation between intron 7 retention and exon
7 skipping, suggesting that binding of eU1 to the G1C-
5′ss helps define the 3′ss of exon 7 and leads to intron 6
splicing. The relative amount of intron 7-retained prod-
uct varied with different eU1s, with the highest observed
in the presence of eU1-M1C-11 that formed the longest
11-base pair (11-bp) duplex with the G1C-5′ss (Figures 1B
and C). Overall, the extent of continuous base pairing be-
tween eU1 and G1C-5′ss appeared to correlate with the
observed effect on splicing. Consistently, eU1-M1C-6 that
formed a 6-bp duplex with the G1C-5′ss completely lost
the ability to prevent exon 7 skipping (Figure 1C). How-
ever, we observed no correlation between eU1:G1C-5′ss du-
plex size and activation of the cryptic splice sites. For exam-
ple, eU1-M1C-10A, eU1-M1C-9B, eU1-M1C-9C and eU1-
M1C-8A showed very similar levels of cryptic site usage de-
spite variations in the size of eU1:G1C-5′ss duplexes they
formed (Figures 1B and C). The effect on SMN1G1C exon
7 splicing was noticeably different between six eU1s that
formed an 8-bp duplex with theG1C-5′ss.While eU1-M1C-
8A and eU1-M1C-8B substantially prevented exon 7 skip-
ping, eU1-M1C-8C had only a weak effect on SMN1G1C
exon 7 splicing (Figures 1B and C). Of note, eU1-M1C-8A
and eU1-M1C-8C target the same sequence; however, eU1-
M1C-8C forms one less hydrogen bond compared to eU1-
M1C-8A (Figure 1B). This is due to the formation of the
wobble and Watson-Crick base pair by eU1-M1C-8C and
eU1-M1C-8A with the G residue at the -2 position of the
G1C-5′ss, respectively (Figure 1B). Hence, our findings rep-
resent a drastic change in the outcome of splicing due to the
mere difference in a single hydrogen bond formed between
a U1 snRNA and its 5′ss target.
Effect of eU1s targeting intronic GU residues downstream of
the G1C-5′ss
In search of an additional cryptic 5′ss that could be ac-
tivated downstream of the G1C-5′ss, we employed eU1s
that targeted six 5′ss-like sequences harboring a GU din-
ucleotide (sites 1 through 6) located within the first 90 nu-
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cleotides of intron 7 (Figure 2A). We refer to these eU1s
as S series (splice-site series) eU1s. They were designed to
form an 11-bp duplex with their respective targets, which
encompass three nucleotides upstream and six nucleotides
downstream of a GU dinucleotide. We used wtU1 and eU1-
M1C-11 as controls. Note that sites 2 and 4 correspond to
Cr1 andCr2, respectively (Figures 1A and 2A).As perMax-
EntScan algorithm, the strength of Cr2 was greater than
Cr1 followed by the rest of the sites (Supplementary Table
S2). The HBond algorithm, which scores 5′ss based on the
hydrogen bonds of the RNA:RNA duplex (formed between
U1 snRNA and the 5′ss) also ranked Cr2 the highest, fol-
lowed by site 3 and then Cr1 (Supplementary Table S3). The
majority of the S series eU1s we employed prevented exon
7 skipping and Cr1 was the most commonly used 5′ss when
the six downstream sites were targeted by eU1s (Figure 2B).
Both eU1-I7S2 (engineered U1 against Intron 7 Site 2) and
eU1-I7S3 that annealed to sites 2 and 3, respectively, pro-
duced the highest levels of exon 7 inclusion generated by
the activation of Cr1 (Figure 2B). Interestingly, eU1-I7S4
that directly targeted Cr2 activated Cr2 ∼3 times less effi-
ciently than Cr1 (Figure 2B). Also, eU1-I7S4 was less effi-
cient in preventing exon 7 skipping compared to eU1-I7S3.
Note that the annealing regions of these two eU1s differ by
only 5 nts. In addition, eU1-I7S4 is predicted to form 27
hydrogen bonds with its target versus 24 predicted for eU1-
I7S3. Among six intron 7-targeting eU1s, eU1-I7S5 was the
least effective in preventing skipping of exon 7 (Figure 2B).
Interestingly, eU1-I7S6 that annealed to the most down-
stream site 6 was more effective in preventing skipping of
exon 7 compared to eU1-I7S5, although it was due to in-
creased intron 7 retention rather than the activation of Cr1
or Cr2 (Figure 2B). We also examined whether eU1s could
activate Cr1 and/or Cr2 in transcripts derived from endoge-
nous SMN1 and SMN2. Indeed, we captured small but de-
tectable levels of Cr1 activation in both SMN1 and SMN2
(Supplementary Figure S4). These results suggested that the
activation of Cr1 is not an artifact of minigenes.
We next examined whether eU1s targeting intronic se-
quences could also activate Cr1 in the context of the wt-5′ss
of exon 7 in the SMN2 minigene. As a control, we used a
previously described mutant U1, eU1-wt-11, which possess
perfect complementarity to the wt-5′ss exon 7 and prevents
SMN2 exon 7 skipping [Figure 2C, (38)]. Except for eU1-
I7S5, all eU1s annealing downstream of the wt-5′ss of exon
7 promoted inclusion of exon 7 albeit with varying degrees.
While all S series eU1s promoted SMN2 exon 7 inclusion
through the usage of the wt-5′ss, we observed slight but no-
ticeable activation of Cr1 when sites 2 and 3 were directly
targeted by eU1-I7S2 and eU1-I7S3, respectively. However,
we did not observe activation of Cr2 by any of the eU1s
employed in the context of SMN2. We noted differential
effects of eU1s on exon 7 splicing between the SMN2 and
SMN1G1C minigenes. For example, in SMN2 eU1-MI7S1
promoted exon 7 inclusion from the wt-5′ss more effectively
than eU1-MI7S2 (Figure 2C). However, the overall exon
7 inclusion using both the wt-5′ss and Cr1 sites was com-
parable for these two eU1s (Figure 2C). In the context of
SMN1G1C, eU1-I7S1 utilized Cr1 very inefficiently as com-
pared to eU1-I7S2 and caused predominant intron 7 reten-
tion (Figure 2B). Furthermore, eU1-I7S4 had a markedly
better effect on preventing exon 7 skipping in the context
of SMN2 than in SMN1G1C (Figures 2B and C). In fact,
eU1-I7S4was among the top two eU1s that caused the high-
est percentage of exon 7 inclusion when co-expressed with
SMN2 (Figure 2C). Levels of exon 7 inclusion promoted by
eU1-I7S4 and eU1-I7S3 were comparable to that of eU1-
wt-11. Of note, in the context of endogenous SMN2, the ef-
fect of overexpressed eU1-I7S3 and eU1-I7S2was compara-
ble to that produced by eU1-wt-11 (Supplementary Figure
S4). Overall, when the wt-5′ss of exon 7 was not mutated,
eU1s targeting intron 7 performed much better in promot-
ing exon 7 inclusion predominantly through activation of
the wt-5′ss. Similar to its effect on exon 7 in the context
of SMN1G1C, eU1-I7S5 was unable to alter the splicing of
SMN2 exon 7 (Figures 2B and C).
It has been shown that the base pair interactions between
U6 snRNA and the 5′ss determine the selection of the 5′
cleavage site (61). Therefore, we compared potential base
pairing of U6 snRNA with the wild, mutated and cryptic
5′ss of exon 7. We observed no clear correlation between
the 5′ss usage and the strength of the base pair interactions
with U6 snRNA (Figure 2D). We also examined the effect
of eU1s targeting intronic sequences on splicing of exon 7 in
the SMN1G1A and SMN1G1U minigenes in which the 5′ss of
exon 7 was rendered inactive by G1A and G1U mutations,
respectively. As with the SMN1G1Cminigene, eU1s did not
activate themutated 5′ss and eU1-I7S3wasmost effective in
promoting exon 7 inclusionmainly through the usage ofCr1
in both SMN1G1A and SMN1G1U (Supplementary Figure
S5).
Effect of eU1:Cr1 duplex size on activation of Cr1
Having shown that Cr1 is activated by three S series eU1s
that target intronic sequences downstream of the G1C-5′ss,
we next asked if the size of the RNA:RNA duplex formed
between an eU1 and Cr1 has an effect on the activation
of Cr1. To address this question, we generated a library of
eU1s that directly targeted Cr1 and for which the number
of base pairs with this site ranged from six to eleven (Figure
3A). The exact annealing positions within Cr1 varied for
each eU1 (Figure 3A). We co-transfected each eU1 with the
SMN1G1Cminigene andmonitored exon 7 splicing 24 h post
transfection. Irrespective of the size of the eU1:Cr1 duplex,
most eU1s rescued exon 7 skipping via Cr1 activation rather
than through intron 7 retention (Figure 3B). eU1-I7S2 that
formed the largest 11-bp eU1:Cr1 duplex caused the highest
intron 7 retention and least Cr1 activation compared to all
other ‘effective’ eU1s targeting Cr1 (Figure 3B). eU1-I7S2-
3+6 that formed a 9-bp eU1:Cr1 duplex caused the high-
est eU1-induced exon 7 inclusion through Cr1 activation.
This increase in inclusion of exon 7 by eU1-I7S2-3+6 was
achieved at the expense of a reduction in intron 7 retention
(Figure 3B). Overall, there appeared to be no straightfor-
ward correlation between Cr1 usage and the size/strength
of eU1:Cr1 duplex. For example, both eU1-I7S2-3+6 and
eU1-I7S2-2+7 formed a 9-bp duplex with Cr1, yet eU1-
I7S2-3+6 performed noticeably better. Of note, eU1-I7S2-
3+6 is calculated to form 20 hydrogen bonds, while eU1-
I7S2-2+7 forms 21 hydrogen bonds. While a lesser num-
ber of hydrogen bonds may seem to be preferable, eU1-
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Figure 2. Effect of eU1s that target ‘GU’ sites within intron 7 on splicing of exon 7. (A) Diagrammatic representation of eU1s and their annealing sites
within intron 7. The GU dinucleotides are indicated by red letters and eU1 annealing sites (3 nts upstream and six nts downstream of each GU) are
underlined. (B) In vivo splicing pattern of SMN1G1C minigene in the presence of overexpressed eU1s shown in (A). Quantification of the relative amount of
the indicated splice products is given in the right panel as a bar diagram. Error bars represent standard error. (C) In vivo splicing pattern of SMN2minigene
in the presence of overexpressed eU1s shown in (A). Quantification of the relative amount of the indicated splice products is given in the right panel as a
bar diagram. Error bars represent standard error. (D) Diagrammatic representation of potential base pairing between wild type U1 and U6 snRNAs with
the indicated 5′ss. The conserved U6 hexanucleotide is underlined. GU dinucleotides are shown in red letters. Pathogenic G1C mutation is shown in blue.
Base pairing is marked by black dots; red dots represent a wobble base pair. Labeling and abbreviations are the same as in Figure 1.
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Figure 3. Effect of decreased base pairing on the ability of a Cr1-targeting eU1 to promote inclusion of exon 7 in SMN1G1C transcripts. (A) Diagrammatic
representation of eU1-I7S2 variants that form different numbers of continuous base pairs with site 2 (Cr1). The eU1-I7S2 variants are grouped in four sets
according to their ability to form base pairs with three nts upstreamof theGU inCr1. The names of theU1 variants as well as the number of hydrogen bonds
they form with Cr1 are given. (B) In vivo splicing pattern of the SMN1G1C minigene in the presence of overexpressed eU1s shown in (A). Quantification
of the relative amount of the indicated splice products is given in the bottom panel as a bar diagram. Error bars represent standard error. Labeling and
abbreviations are the same as in Figure 1.
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I7S2-3+7 (23 hydrogen bonds) activated Cr1 better than
eU1-I7S2-2+7 (Figure 3B). Consistent with these results,
eU1s that formed different sizes of eU1:Cr1 duplexes ac-
tivated Cr1 with similar efficiency (Figure 3B), so long as
they formed at least 8 continuous base pairs, with the ex-
ception of eU1-I7S2-0+6, whose ability to activate Cr1 was
comparable to that of the eU1s that formedmuch longer du-
plexes with their corresponding targets within Cr1. This in-
dicates that not only the number of continuous nucleotides
involved in base pairing with U1 snRNA is important for
the efficiency of the 5′ss activation/usage but also their po-
sition relative to a GU dinucleotide within this site.
Effect of eU1s on splicing of exon 7 of SMN1 carrying mu-
tations at the 3′ss of SMN1 exon 7
To determine if eU1s that activated Cr1 would also have
a stimulatory effect on exon 7 inclusion in the context
of an abrogated 3′ss, we generated the SMN1G-1Uand
SMN2G-1Uminigenes that carried a G-to-T mutation (G-
1U) at the last position of intron 6 (Figure 4A). We
co-transfected these minigenes with Cr1-activating eU1s
(eU1-I7S2 and eU1-I7S3) and determined the splicing of
exon 7 ∼24 h post transfection. As controls, we used
wtU1 and eU1-wt-11 that formed 6-bp and 11-bp duplexes
at the wt-5′ss of exon 7, respectively. As expected, both
SMN1G-1U and SMN2G-1U showed complete skipping of
exon 7 (Figure 4B). However, eU1-I7S2 that directly tar-
geted Cr1 rescued exon 7 inclusion predominantly through
the usage of the wt-5′ss and the activation of a cryptic 3′ss
(E7-3′Cr) located within exon 7 in both SMN1G-1U and
SMN2G-1U transcripts (Figure 4B). These results confirmed
that an eU1 annealing to a downstream intronic sequence
away from a functional 5′ss can define both the 3′ss and
5′ss of an upstream exon. However, there appeared to be
a distance limitation for this type of mechanism of action,
since eU1-I7S3 that targeted sequences downstream of Cr1
turned out to be less effective in promoting exon 7 inclusion
in the context ofSMN1G-1U and failed to do so inSMN2G-1U
transcripts (Figure 4B). The predicted strengths of E7-3′Cr
were very similar for both SMN1 and SMN2 (Supplemen-
tary Table S2). Hence, the inability of eU1-I7S3 to pro-
mote exon 7 inclusion in the context of SMN2G-1U could
be due to several reasons. For example, E7-3′Cr is partially
sequestered by terminal stem loop 1 (TSL1) that is strength-
ened by the SMN2-specific C6U mutation within exon 7
(52). Further, C6Uhas been proposed to create binding sites
for Sam68 and hnRNPA1, which are negative regulators of
SMN2 exon 7 splicing [Figure 4A, (62,63)]. Hence, it is likely
that the strengthened TSL1 and/or interactions of Sam68
and hnRNP A1 within SMN2 exon 7 renders the E7-3′Cr
inaccessible to the spliceosomal machinery.
eU1s rescue aberrant splicing caused by a variety of muta-
tions associated with SMA
We expanded our study to examine the effect of eU1s
on splicing of exon 7 in the SMN1U6G, SMN1ΔPy
and SMN1Δ4-5
′ ssminigenes encompassing three dif-
ferent pathogenic mutations associated with SMA.
SMN1U6Grepresented a SMA type 3 patient with a T-to-G
mutation at the sixth position (U6G in RNA) of intron
7 of SMN1 [Figure 5A, (64)]. Of note, while U6G-5′ss
is predicted to be weaker than the wt-5′ss of exon 7, it
scored better than Cr1 (Supplementary Tables S2 and
S3). SMN1ΔPyrepresented a SMA type 1 patient with
a 7-nt deletion in the polypyrimidine tract (PPT) up-
stream of the 3′ss of SMN1 exon 7 [Figure 5A, (27)].
SMN1Δ4-5
′ ssrepresented a SMA type 2 patient with a 4-nt
deletion from the fourth to seventh positions of intron 7
of SMN1 [Figure 5A, (27)]. Similar to U6G-5′ss, 4-5′ss
is weaker than wt-5′ss but is predicted to be stronger than
Cr1 (Supplementary Tables S2 and S3). As expected, all the
SMN1 minigenes harboring pathogenic mutations showed
massive skipping of exon 7 (Figure 5B). For SMN1U6G
and SMN1Δ4-5
′ ssthat carried mutations within the 5′ss,
we also observed usage of Cr1 and to a lesser degree
Cr2 and E6Cr (Figure 5B, lanes 9 and 23). While usage
of the U6G-5′ss was significantly decreased, we did not
detect usage of 4-5′ss (Figure 5B). We next compared
the effect of the most effective S series eU1s on splicing
of exon 7 of the SMN1 minigenes carrying the above-
mentioned pathogenic mutations. In the case of SMN1U6G,
the annealing position of eU1 dictated which 5′ss would
be used. For example, while eU1-wt-11 promoted usage
of the U6G-5′ss, eU1-I7S2 and eU1-I7S3 predominantly
activated Cr1 (Figure 5B, compare lane 11 to lanes 13
and 14). In the case of SMN1ΔPy, both eU1-I7S2 and
eU1-I7S3 prevented SMN1ΔPy exon 7 skipping as well
as promoted exon 7 inclusion predominantly through the
usage of the wt-5′ss of SMN1ΔPyexon 7 (Figure 5B, lanes
20 and 21). However, eU1-I7S2 also activated Cr1 to a
detectable level (Figure 5B, lane 20). Interestingly, despite
its perfect complementarity to the wt-5′ss, eU1-wt-11 was
less effective in promoting inclusion of SMN1ΔPy exon 7
(Figure 5B, lane 19). This could be due to close proximity
of its annealing site to the 3′ss of exon 7. In the context
of SMN1Δ4-5
′ ss, most U1s predominantly activated Cr1
(Figure 5B). eU1-M4-11 that annealed to the4-5′ss was
an exception as its overexpression mostly produced intron
7-retained transcripts (Figure 5B, lane 26).
Effect of eU1s that target random sequences on SMN exon 7
splicing
We next examined the effect of what we called R se-
ries (random series) eU1s that targeted random sequences
downstream and upstream of the 5′ss of exon 7 on splic-
ing of this exon in the context of the SMN2, SMN1G1C and
SMN1U6G minigenes (Figure 6A). The targets of R series
eU1s lacked GU residues that are essential for the usage of
the 5′ss in human U2 type introns. Similar to the S series
eU1s, all R series eU1s were designed to form an 11 bp du-
plex with their respective targets. In the case of SMN1G1C,
eU1-I7R7 (engineered U1 against Intron 7 Random se-
quence 7) and eU1-I7R8 that annealed to sequences imme-
diately downstream and upstream of Cr1, respectively, pro-
duced the best effect on activation of Cr1 among all eU1s
we used, including S series eU1s (Figure 6B, lanes 6 and
8). There appeared to be no direct correlation between the
number of hydrogen bonds and the efficacy of a given eU1,
since eU1-I7R7 and eU1-I7R8 showed similar efficacy in
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Figure 4. Effect of eU1s on splicing of exon 7 with a mutated 3′ ss of SMN exon 7. (A) Diagrammatic representation of eU1s and their target sites within
SMN transcripts carrying the mutated 3′ss of exon 7. Labeling is the same as in Figure 2A. Splice sites are indicated by arrows. The binding sites for
Sam68 and hnRNP A1, known to promote skipping of exon 7 (62,63), are highlighted (bottom diagram). (B) In vivo splicing pattern of the SMN1G-1U and
SMN2G-1U transcripts in the presence of overexpressed eU1s shown in (A). Labeling is the same as in Figure 1C. Quantification of the relative amount of
the indicated splice products is given in the bottom panel as a bar diagram. Error bars represent standard error. Asterisks indicate splice products in which
the cryptic 3′ss in exon 7 was used for splicing. Labeling and abbreviations are the same as in Figures 1 and 2.
Cr1 activation despite forming 24 and 26 hydrogen bonds
with their respective targets (Figure 6). In the context of
SMN1G1C, eU1-I7R10 that annealed to exon 7 showed a
high propensity for intron 7 retention rather than Cr1 acti-
vation (Figure 6B). This effect was similar to the one pro-
duced by U1s that targeted the mutated 5′ss or site 1. How-
ever, eU1s that annealed downstream of site 1 effectively
activated Cr1. At the same time, while eU1s targeting se-
quences downstream of site 3 prevented SMN1G1Cexon 7
skipping to varying degrees, they were not as effective as
those targeting site 3 or the sequences upstream of it (Fig-
ure 6B). To determine the effect of duplex size formed be-
tween aR series eU1 and its target onCr1 activation, we em-
ployed a library of eU1-I7R7 variants with different degree
of complementarity to their target site in the context of the
SMN1G1C minigene. All eU1-I7R7 variants that formed du-
plexes of 8 bp or greater activated Cr1 with comparable ef-
ficiency (Supplementary Figure S6). eU1-I7R7-D-8 was an
exception. In fact, our results suggested that in addition to
the duplex size, positions of nucleotides at the 5′ end of eU1
involved in target recognition played an important role in
Cr1 activation. For example, eU1-I7R7-D-8 and eU1-I7R7-
E-8 are designed to anneal to the same sequence within in-
tron 7, and yet the latter eU1 performed significantly better
in Cr1 activation (Supplementary Figure S6, lanes 17 and
19).
In the context of SMN2, all eU1s that we employed effec-
tively promoted exon 7 inclusion utilizing the wt-5′ss; how-
ever, we also observed some activation of Cr1 by eU1-I7R7,
eU1-I7R8 and eU1-I7S3 that annealed in the vicinity of Cr1
(Figure 6B, lanes 16–18). The efficiency of eU1-I7R7, eU1-
I7R8, eU1-I7R9, eU1-I7S3, eU1-I7S4 and eU1-I7R10 in
activation of the wt-5′ss was comparable to that of the eU1-
wt-11. Of note, employing SMN2 minigene, we also tested
the efficacy of eU1s that targeted the predicted cryptic splice
site within exon 7 or sequences more than 100 nts down-
stream of the wt-5′ss of exon 7. None of these eU1s showed
a stimulatory effect on SMN2 exon 7 splicing (not shown).
We observed somewhat different effects of eU1s on splicing
of exon 7 of SMN1U6G in which most eU1s promoted exon
7 inclusion through activation of Cr1 (Figure 6B). The ex-
ceptions were eU1-M6G-11 and eU1-I7R10 that annealed
to the U6G-5′ss and the upstream sequence within exon
7, respectively. These two eU1s mostly favored intron 7 re-
tention followed by usage of U6G-5′ss. Another engineered
U1, eU1-I7S1, activated both U6G-5′ss and Cr1 sites to a
comparable degree (Figure 6B, lane 29).Note that eU1-I7S1
annealed to the region that overlapped the U6G-5′ss; how-
ever, the complementarity of eU1-I7S1 with its target site is
interrupted due to theU6Gmutation. eU1s that annealed in
the immediate vicinity of Cr1, such as eU1-I7R7 and eU1-
I7R8, activated Cr1. The intensity of the band correspond-
ing to the usage of Cr2 was significantly decreased in the
presence of these eU1s (Figure 6B, lanes 31 and 33). Simi-
larly, overexpression of eU1s that annealed downstream of
Cr1, such as eU1-I7S3, eU1-I7S4 and eU1-I7R9 also pro-
moted the usage of Cr1. In addition, eU1-I7R9 and eU1-
I7S4 that targeted site 4 (Cr2) activated Cr2 to some degree
(Figure 6B, lanes 34 and 35). Overall, our results show that
in the context of several competing 5′ss (as in the case of
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Figure 5. Effect of eU1s on splicing of transcripts generated by SMN1minigenes carrying pathogenic mutations. (A) Diagrammatic representation of eU1s
and their targets within SMN1 carrying SMA-associated splicing mutations. Labeling is the same as in Figures 1B and 2A. (B) In vivo splicing pattern
of the SMN1 mutant minigenes in the presence of overexpressed eU1s shown in (A). Labeling is the same as in Figure 1C. Quantification of the relative
amount of the indicated splice products is given in the right panel as a bar diagram. Error bars represent standard error. Labeling and abbreviations are
the same as in Figures 1 and 2.
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Figure 6. Ability of different eU1s to promote inclusion of exon 7 in transcripts generated by various SMN minigenes. (A) Diagrammatic representation
of eU1s and their targets. All eU1s formed 11 base pairs with their corresponding targets. (B) In vivo splicing pattern of the indicated minigenes in the
presence of overexpressed eU1s shown in (A). Quantification of the relative amount of the indicated splice products is given as bar diagrams (right panels).
Error bars represent standard error. Labeling and abbreviations are the same as in Figures 1 and 2.
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SMN1U6G exon 7), the proximity of eU1 annealing deter-
mines which site will be used.
Point mutations activate Cr1 and Cr2
We next tested if strengthening of the cryptic splice sites
will enhance their usage in the context of SMN1, SMN2
and SMN1G1C minigenes. We made four point mutations
(A23G, G26A, A28G and C30A) and one double mutation
(A23G/A28G) in Cr1 and three point mutations (U50A,
U54A and U55A) in Cr2 (Figure 7A). All mutations in-
creased complementarity with wtU1. Among all mutations
within Cr1 and Cr2, A28G and U54A strengthened their
corresponding sites the most (Supplementary Tables S2 and
S3). Depending on the minigene used, we observed differ-
ent effects of mutations on splicing of exon 7 (Figure 7B).
While G26A, C30A and U55A did not significantly change
the splicing of any minigenes, A23G, A28G and U54A all
produced a strong splicing switch. For example, A23G and
A28G mutations resulted in complete inclusion of exon 7
through activation of Cr1 exclusively, in both SMN1 and
SMN2 transcripts (Figure 7B, lanes 2, 4, 20 and 22). Of
note, A23G andA28G extended the size of Cr1:endogenous
U1 duplex from 4 to 6 continuous base pairs, which is the
same as the size of the duplex formed between endogenous
U1 and the wt-5′ss of exon 7. Yet, usage of the latter 5′ss
was completely abolished in the presence of A23G or A28G
substitutions. Compared to point mutations within the Cr1
site, the U50A and U54A substitutions had a lesser effect
on activation of Cr2 in the context of the SMN1 and SMN2
minigenes (Figure 7B). This could be due to the fact that the
duplex formed between endogenous U1 and Cr2 carrying
either U50A or U54A remained relatively short. However,
in the context of the SMN1G1C minigene, both substitutions
resulted in almost complete inclusion of exon 7 though ac-
tivation of Cr2 (Figure 7B, lanes 16 and 17).
It has been previously shown that mutations within the
Tra2 exonic splicing enhancer (ESE) cause massive skip-
ping of exon 7 (38). Interestingly, A23G and A28G mu-
tations within intron 7 rescued the inclusion of exon 7 in
SMN2 minigene carrying a mutation that abrogated Tra2
ESE (Figure 7B, lanes 29–32). Earlier we reported that A
to G substitution at the last position of exon 7 (-1G substi-
tution) confers one of the strongest stimulatory effects on
SMN2 exon 7 inclusion through the enhanced usage of the
5′ss (37). When -1G substitution was combined with the in-
tronic A23G/A28G mutations in the SMN2 minigene, we
observed an increase in exon 7 inclusion through the usage
of both 5′ss and Cr1 (Figure 7B, lane 33). These results con-
firm that the strength of Cr1 carrying A23G/A28G muta-
tions is comparable to that of the native 5′ss carrying -1G
substitution. Of note, –1G produces the strongest stimula-
tory effect caused by a single nucleotide change within exon
7. While site 3 is not used in the context of any of the mini-
genes or in the presence of any eU1 we employed, a U-to-
G mutation at the 38th intronic position (U38G) did acti-
vate this site resulting in predominant inclusion of exon 7,
but only in the context of the SMN1G1Cand SMN1U6G tran-
scripts (Figure 7B). In SMN2 transcripts, U38G had some
stimulatory effect on exon 7 inclusion as well but through
the usage of the wt-5′ss (Figure 7B, lanes 39 and 41).
Effect of mutations within ISS-N1 and URC1 on usage of
Cr1
We next attempted to identify splicing regulatory elements
that specifically control usage of Cr1. As mentioned above,
Cr1 partially overlaps with both the inhibitory element ISS-
N1 and the stimulatory element URC1 (Figures 1A and
8A). Consistent with a previous report, an A-to-Cmutation
at the 12th intronic position (A12C mutation) promoted
SMN2 exon 7 inclusion by abrogating one of the hnRNP
A1/A2motives of ISS-N1 [Figure 8B, (43)].However,A12C
mutation did not activate Cr1 in SMN2 (Figure 8B, lane
2). Similarly, we observed no usage of Cr1 in SMN1 and
SMN1U6G transcripts in the presence of A12C (Figure 8B,
lanes 4 and 7), suggesting that this hnRNP A1/A2 motif
is not critical for Cr1 usage in the context of either wt-5′ss
or U6G-5′ss. We next introduced a U-to-G and an A-to-G
substitution at the 19th and 21st positions (U19G/A21G
mutation) of SMN intron 7, respectively. This double mu-
tation created a classical UUAGGGmotif that tightly inter-
acts with hnRNP A1 (65). As expected, U19G/A21G mu-
tation increased skipping of SMN1 exon 7 (Figure 8B, lane
5). In SMN1U6G transcripts, U19G/A21G mutation led to
complete skipping of exon 7 (Figure 8B, lane 8). We did
not observe specific suppression of Cr1 in the presence of
U19G/A21G, instead usage of all three competing 5′ss (wt-
5′ss, Cr1 and Cr2) was abrogated (Figure 8B, lane 8). These
results suggest that although ISS-N1 might contribute to
Cr1 suppression, it is not a specific regulator of Cr1.
We also investigated the extent to which natural varia-
tion in the sequence of SMN intron 7 may impact usage of
Cr1 and/or Cr2. First, we aligned the sequences of SMN
exon 7 and the first 100 bases of intron 7 derived from
11 mammalian species (Supplementary Figure S7). As ex-
pected, exon 7 was relatively well conserved. Surprisingly,
many of the intronic sequences near the 5′ss were also con-
served, especiallyURCs 1 and 2 (SupplementaryFigure S7).
Cr1 and Cr2 were not universally conserved, but were still
present in the majority (7 out of 11 for each site) of species
examined. Although the results of U19G/A21Gmutant in-
dicate that a strong hnRNP A1/A2 site in ISS-N1 might
play a role in Cr1 suppression, this region of ISS-N1 does
not appear to be well conserved in mammals (Supplemen-
tary Figure S7). Consistently, a common single nucleotide
polymorphism (SNP) in humans changes the G residue at
position 20 into a C, likely weakening or abrogating the hn-
RNP A1/A2 motif altogether (Supplementary Figure S7).
Indeed, in the context of the SMN2 minigene G20C muta-
tion causes noticeable increase in inclusion of exon 7 (Sup-
plementary Figure S8, lane 3). However, G20C did not in-
crease usage of Cr1, even when the SMN2 minigene carry-
ing this mutation was co-transfected with eU1-I7S3 shown
to activateCr1 (SupplementaryFigure S8, lane 6 versus lane
7).While URC1 is well conserved, there is a SNP in humans
that alters this motif, changing the U at position 32 to a
C nucleotide (Supplementary Figure S7). Consistent with
weakening of URC1, SMN2U32C display increased skipping
of exon 7 compared to the wild type SMN2minigene (Sup-
plementary Figure S8). Co-transfection with eU1 is able to
efficiently rescue exon 7 skipping in SMN2U32C, but primar-
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Figure 7. Effect of site-specific mutations on usage of the wt and cryptic 5′ss of SMN. (A) Diagrammatic representation of site-specific mutations within
exon 7 and/or intron 7 of SMN. Exon 7 and intron 7 nucleotides are shown in capital and lower-case letters, respectively. Positive and negative numbering
starts from the first position of intron 7 and the last position of exon 7, respectively. The location and identity of each mutation is indicated. The GU
dinucleotides are shown in red letters. GU-containing sites within intron 7, including site 2 (Cr1) and site 4 (Cr2), are underlined. The 5′ss is indicated by
an arrow. ISS-N1 and Tra2-1 binding site are highlighted with a pink and green boxes, respectively (37,37). (+) and (–) indicate that an element promotes
inclusion and skipping of exon 7, respectively. (B) In vivo splicing pattern of the indicated minigenes carrying site-specific mutations as compared to the
wild type constructs. Mutations are marked at the top of the gel. Abbreviations: E7 site 3, exon 7-included from the activated site 3. The rest of the labeling
and abbreviations are the same as in Figure 1.
ily through activation of wt-5′ss rather than Cr1 (Supple-
mentary Figure S8).
To further dissect the potential role of URC1 in Cr1 us-
age, we introduced A33U and C34U mutations in SMN1,
SMN2 and SMN1U6G minigenes. These mutations in-
creased the length of the continuous U-rich tract within
URC1. A33U and C34U together or separately had no
effect on splicing of exon 7 in SMN1 and SMN2 tran-
scripts (Figure 8B). However, in SMN1U6G transcripts,
A33U/C34U double mutation completely suppressed us-
age of Cr2, and increased usage of Cr1 over the wt-
5′ss, granted Cr1 was still used inefficiently (Figure 8B,
lane 12 versus lane 11). In our next set of mutations, we
changed pyrimidine residues to purines within URC1 based
on HEXplorer score predictions. HEXplorer score profiles
reflect splicing enhancing and silencing properties of se-
quences neighboring splice sites and is particularly help-
ful in analyzing the effect of mutations on splice site us-
age (66). In SMN1U6G transcripts, U35A/U36A mutation
noticeably decreased usage of Cr1 (Figure 8B, lane 13),
while U37A/U38G/U40A substitutions completely abro-
gated Cr1 and simultaneously increased usage of Cr2 (Fig-
ure 8B, lane 14). Activation of Cr2 was also stimulated by
U40Amutation, which in addition to weakening URC1 ab-
rogated site 3 defined by the presence of a GU dinucleotide
(Figure 8B, lane 15). In the context of theSMN1 andSMN2
minigenes, none of the URC1 mutations activated a cryp-
tic splice site. The U37A/U38G/U40A mutant displayed
substantial skipping of SMN2 exon 7 (Figure 8B, lane 23).
Overall, our results support a point of view that URC1
might control usage of Cr1 in the context of the U6G-
mutated 5′ss but not in the context of the wt-5′ss.
Effect of moving Cr1 away from ISS-N1
In an effort to determine if the suppression of Cr1 is linked
to the presence of ISS-N1, we constructed minigenes in
which wemoved Cr1 away from ISS-N1 by inserting a 26-nt
sequence (Sequence 1) harboring three CCAAACAA mo-
tifs (Figure 9A). Our rationale to use these particular mo-
tifs was based on its neutral effect on splicing as reported
earlier (14,67,68). This insertion will also increase the dis-
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Figure 8. Effect ofmutationswithin ISS-N1 andURC1onCr1 usage. (A)Diagrammatic representation ofmutationswithin ISS-N1 andURC1.Numbering
starts from the first position of intron 7. The location and identity of eachmutation is indicated. GU dinucleotides are marked by red letters. GU-containing
sites within intron 7 are underlined in green.Mutated bases aremarked in blue and indicatedwith arrows. ISS-N1with its hnRNPA1/A2motifs andURCs 1
and 2 are highlighted with pink and green boxes, respectively. (B) In vivo splicing pattern of the indicatedminigenes. The percentage of SMN exon 7 skipping
was calculated as described previously (52). Labeling and abbreviations are the same as in Figures 1 and 7B.
Downloaded from https://academic.oup.com/nar/article-abstract/45/21/12214/4158474
by Iowa State University user
on 21 February 2018
12230 Nucleic Acids Research, 2017, Vol. 45, No. 21
Figure 9. Effect of the distance between ISS-N1 and Cr1 on usage of Cr1. (A) Location of Cr1 within intron 7 of the indicated minigenes with respect
to ISS-N1. ISS-N1 with its two hnRNP A1/A2 binding sites is highlighted by a pink box. URCs 1 and 2 are marked with green boxes. The 5′ss (wt and
mutated) are indicated by arrows. Names of the minigenes are given on the right above each corresponding sequence. Sequence 1 is a 26-nt-long insertion
comprised of three repeats of splicing neutral motif CCAAACAA followed by an AG dinucleotide (shown in lower case letters). Sequence 2 is a 25-nt-long
insert followed by an AG (shown in lower-case letters). Each sequence was inserted immediately down stream of ISS-N1. The AG dinucleotide was added
to restore Cr1. Mutations within intron 7, including the insertion, are shown in blue. The GU dinucleotides are marked by red letters. GU-containing
sites within intron 7, including cryptic sites Cr1 and Cr2, are underlined. (B) In vivo splicing pattern of the indicated minigenes carrying the insertions as
compared to the wt constructs. The identity of the minigenes is indicated at the top of the gels. The identity of splicing products is marked on the left and
the right of the gels. Abbreviations: E7Mv-Cr1, exon 7-included where Mv-Cr1 site was used; the rest of abbreviations are described in Supplementary
Table S1.
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tance between the 5′ss of exon 7 and URC1/URC2 that are
associated with TIA1/TIAR binding (44). Insertion of Se-
quence 1 in SMN1 caused a small but detectable level of
Cr1 activation. We also observed small increase in SMN1
exon 7 skipping and intron 7 retention (Figure 9B, lane 3).
In the case of SMN2, insertion of Sequence 1 did not ac-
tivate Cr1, but caused increased skipping of exon 7 (Figure
9B, lane 4). These results support that a strong 3′ss inSMN1
coupled with moving Cr1 away from ISS-N1 is conducive
for Cr1 activation. Enhanced skipping of SMN2 exon 7
upon insertion of Sequence 1 could be due to a weak 3′ss of
exon 7 coupled with moving of TIA1/TIAR binding sites
(URC1/URC2) away from the weak 5′ss (45). Interestingly,
insertion of Sequence 1 in the context of SMN1G1Cand
SMN1U6G resulted in robust activation of Cr1 accompanied
by a decrease in exon 7 skipping and an increase in intron 7
retention (Figure 9B, lanes 5–8). These results confirm that
when Cr1 is presented in the right context it is inherently
functional/capable of being activated by the endogenous
level of U1 snRNP. Our results support that ISS-N1 con-
tributes towards the suppression of Cr1 usage. As expected,
we observed no effect of insertion of CA-rich Sequence 1
on activation of Cr2 (Figure 9B). To rule out the possibil-
ity that insertion of Sequence 1 created a binding site(s) for
protein factors that affected splicing of exon 7, we tested an
additional sequence, Sequences 2, previously employed by
others as splicing neutral insert (68,69). Sequence 2 has a
length comparable to Sequence 1, but its sequence compo-
sition is entirely different: it contains uridines and guani-
dines that are absent in Sequence 1 (Figure 9A). Insertion
of Sequence 2 between ISS-N1 and Cr1 produced splicing
patterns nearly identical to the ones observed for four SMN
minigenes that contained Sequence 1 (Figure 9). This out-
come independently confirmed that the usage of Cr1 is sup-
pressed by ISS-N1.
We expanded our study to examine if F14, an ISS-N1
blocking ASO, was able to activate Cr1 and rescue exon
7 inclusion in four minigenes that carry SMA-associated
splicing mutations. We deliberately chose F14 because it se-
questers the first 14 residues of ISS-N1 but does not block
the GU dinucleotides of Cr1 (Supplementary Figure S9A).
We have previously shown that F14 is very effective in
restoration of SMN2 exon 7 inclusion (54). Therefore, the
SMN2 minigene was used as a positive control. Increase in
endogenous SMN2 exon 7 inclusion in samples transfected
with the minigenes served as an internal control that F14
was indeed delivered within cells. As expected, F14 restored
exon 7 inclusion in SMN2; it also decreased skipping of
exon 7 in SMN1ΔPy through activation of the wt-5′ss. (Sup-
plementary Figure S9). However, in the case of SMN1mini-
genes with pathogenic mutations at the 5′ss of exon 7, F14
did not produced the expected improvement in exon 7 splic-
ing and further decreased already inefficient usage of Cr1,
Cr2 and the U6G-5′ss (Supplementary Figure S9, lanes 7, 8
and 10). These results suggest that the presence of an ISS-
N1 targeting ASO interferes with one or more steps of the
spliceosomal assembly at the mutated 5′ss as well as at Cr1
and Cr2.
Activation of Cr1 by eU1 is independent of the endogenous
U1 snRNP
It has been recently shown that endogenous U1 snRNP is
not required for an eU1-mediated activation of an authentic
5′ss (26). However, it is not known if this is also the case for
the activation of a cryptic splice site. To address this ques-
tion, we co-transfected SMN2 and SMN1G1C minigenes
with eU1-I7R7 with or without an 11-mer U1 ASO com-
plementary to the 5′-tail of the wtU1 (Figure 10A). Note
that the annealing site of eU1-I7R7 only partially overlaps
with Cr1. The U1 ASO we used has little complementarity
with eU1-I7R7; hence it is unlikely to have an effect on the
activity of this eU1 (Figure 10A). To monitor that the U1
ASO has inactivated endogenous U1 snRNP, in addition
to splicing of exon 7 in SMN2 minigene, we also analyzed
splicing of endogenous SMN1 and SMN2 exon 7 as well
as splicing of all SMN exons in a single reaction by using
MESDA (55). As an additional control for an efficient in-
activation of endogenous U1, we assessed the ability of F14
to promote exon 7 inclusion, whichwas previously shown to
rely on the presence of endogenous U1 (26), in the absence
and presence of the U1 ASO. Similar to the previous study
(26), our treatment of HeLa cells with 200 nM of the U1
ASO abrogated the stimulatory effect of F14 (Figure 10B,
lane 7 versus line 9) confirming that endogenousU1 snRNA
was sufficiently depleted. Furthermore, in agreement with
the prevailing hypothesis that the poor recruitment of U1
snRNP at the wt-5′ss is the limiting factor for exon 7 splic-
ing (33,34), ASO-mediated inactivation of endogenous U1
snRNP caused massive skipping of exon 7 in transcripts
derived from SMN2 minigene as well as from endogenous
SMN1 and SMN2 (Figure 10B, lane 4 and Figure 10C, lane
4 and 9). In addition, effective inactivation of endogenous
U1 was confirmed by the results of MESDA that showed
that U1 ASO treatment caused massive skipping of mul-
tiple SMN exons (Figure 10D). As expected, when SMN2
and SMN1G1C were co-transfected with eU1-I7R7, we ob-
served Cr1 activation in transcripts derived from bothmini-
genes (Figure 10B, lanes 3 and 13). In the case of SMN1G1C,
the activation of Cr1 produced the major spliced product
(Figure 10B, lane 13). When overexpression of eU1-I7R7
was combined with the U1 ASO treatment, the usage of
Cr1 appears to be mostly unaffected both in SMN2 and
SMN1G1C transcripts (Figure 10B, lane 5 and 15). How-
ever, eU1-I7R7-induced usage of the wt-5′ss in SMN2 tran-
scripts was significantly decreased in the presence of the U1
ASO (Figure 10B, lane 5). Similarly, eU1-I7R7 was unable
to fully prevent skipping of exon 7 from endogenous SMN
transcripts when endogenous U1 was depleted (Figure 10C,
lane 5 and 10). These results confirmed that eU1 could acti-
vate a cryptic splice site without the help of endogenousU1.
However, contrary to the previous report (26), our results
suggest that the assistance of endogenous U1 is required for
an eU1-induced improvement in the usage of the wt-5′ ss of
exon 7.
Effect of hnRNP A1/A2 depletion on activation of cryptic
splice sites
Given the presence of two hnRNP A1/A2 motifs within
ISS-N1 that partially overlaps with Cr1 and, as we have
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Figure 10. Ability of an eU1 to activate Cr1 under conditions of the inactivation of the endogenous U1 by an ASO. (A) Diagrammatic representation of
eU1 and ASOs used to affect splicing of SMN exon 7. Left panel indicates location of eU1 and F14 ASO within SMN intron 7. Right two panels indicate
complementarity of U1 ASO to wtU1 snRNA and eU1-I7R7 snRNA. (B) In vivo splicing pattern of the indicated minigenes in the presence of various
ASOs and eU1. Co-transfected minigenes, eU1, and ASO are indicated at the top of each gel. Splice products are indicated on the left and right of each gel.
(C) In vivo splicing pattern of endogenous SMN1 and SMN2 in the presence of various ASOs and eU1. Sample identities are indicated at the top of each
gel and refer to sample numbers in (B). Spliced products amplified by RT-PCR were digested with DdeI to distinguish between the transcripts originated
from SMN1 and SMN2 (29). The percentage of SMN2 exon skipping was calculated as described previously (48). 3′Ex8 represents the cleavage product
of DdeI digestion of SMN2 exon 8. The rest of the abbreviations are the same as in Figure 1C. (D) Multi-exon skipping detection assay (MESDA; 55–58)
showing splicing pattern of all internal exons of endogenous SMN. Sample identities are indicated at the top of each gel and refer to sample numbers in
(B). Identities of splicing products are indicated to the left or right of each gel. Abbreviations: FL, full-length SMN; , skipped exon(s). Labeling is the
same as in Figure 1. Abbreviations are described in Supplementary Table S1.
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shown, suppresses its usage, we asked if the siRNA-
mediated depletion of these proteins would activate Cr1.
In these experiments we used SMN1G1C and SMN1U6G
minigenes to avoid any likely competition between Cr1
and the wt-5′ss. Of note, SMN2 contains several hnRNP
A1/A2 binding sites and the depletion of hnRNP A1/A2
has been shown to reduce skipping of exon 7 from en-
dogenous SMN2 (48). Hence, splicing of endogenous exon
7 served as a control for checking the efficiency of the
siRNA-mediated depletion of hnRNP A1/A2. To ensure
that robust knockdown of hnRNP A1/A2 was achieved,
we treated HeLa cells with siRNAs twice before transfect-
ing them with either SMN1G1C or SMN1U6G (Figure 11A).
In the case of SMN1G1C, we did not observe a change in the
splicing/usage of any of the splice sites, including Cr1, upon
depletion of hnRNP A1/A2 (Figure 11C). The absence of
Cr1 activation was not due to high levels of residual hnRNP
A1/A2, since western blot confirmed substantial depletion
of these proteins (Figure 11A). In addition, the levels of hn-
RNPA1/A2 knockdown were sufficient enough to result in
reduced skipping of exon 7 from endogenous SMN2 in cells
transfected with SMN1G1Cor SMN1U6G minigene (Figure
11B). Unlike SMN1G1C, SMN1U6G showed significant acti-
vation of Cr1 when hnRNP A1/A2 were depleted. The us-
age of the U6G-5′ss was increased as well (Figure 11C). We
also observed small but noticeable increase in the usage of
Cr2 and E6Cr (Figure 11C, lane 4 versus lane 3). These re-
sults support some role of hnRNP A1/A2 in suppression
of Cr1 (at least in the context of SMN1U6G). However, this
role is not specific to Cr1, since other 5′ss were activated as
well. Our results also suggest that Cr1 is a stronger 5′ss as
compared to theU6G-5′ss. The disparity in the splicing pat-
tern between SMN1G1Cand SMN1U6G with respect to the
activation of Cr1 under the conditions of hnRNP A1/A2
depletion was somewhat unexpected but not totally surpris-
ing.We attribute these differences to the partially functional
U6G-5′ss that may recruit stimulatory factors conducive to
the activation of Cr1.
mRNAs generated by the eU1-induced activation of Cr1 pro-
duce full-length SMN
To determine if mRNAs generated by the eU1-induced
activation of Cr1 can produce full-length SMN, we em-
ployed a splicing-coupled translation reporter. In particu-
lar, we constructed FLAG-SMN1 and FLAG-SMN1G1C ex-
pression vectors containing a 3XFLAG tag in-frame with
the residual SMN coding sequence (cDNA corresponding
to exon 1 through exon 5) placed upstream of the SMN1
and SMN1G1C minigenes, respectively (Figure 12A). Inclu-
sion and skipping of exon 7 from these reporter constructs
are expected to generate full-length SMN and SMN7,
respectively. We co-transfected HeLa cells with FLAG-
SMN1G1Cand a Cr1-activating eU1 (eU1-I7R7 or eU1-
I7S3) that annealed to sequences downstream of Cr1 (Fig-
ure 12A). We specifically chose these eU1s since they will
not interfere with nuclear export and translation due to an-
nealing to the processed mRNA. As a negative control, we
used wtU1 that has no effect on splicing of SMN1G1C exon
7 due to its poor complementarity/annealing to the G1C-
5′ss. In vivo splicing and protein expression from FLAG-
SMN1 and FLAG-SMN1G1C constructs were tested ∼24
h post-transfection. As expected, FLAG-SMN1 produced
exon 7-included transcripts (Figure 12B, lane 5). In compar-
ison, only exon 7-skipped transcripts were generated from
FLAG-SMN1G1C(Figure 12B, lanes 1 and 2). Overexpres-
sion of eU1-I7S3 or eU1-I7R7 resulted in predominant in-
clusion of FLAG-SMN1G1C exon 7 due to activation of Cr1
(Figure 12B, lanes 3 and 4). In the absence of Cr1 acti-
vation, low levels of SMN7 were expressed from FLAG-
SMN1G1C(Figure 12C, lanes 1 and 2). Of note, a low level
of SMN7 can be attributed to its poor stability (31). Con-
sistent with exon 7 inclusion through Cr1 activation, we ob-
served full-length SMNprotein as the predominant product
generated from FLAG-SMN1G1Cin the presence of overex-
pressed eU1-I7S3 or eU1-I7R7 (Figure 12C, lanes 3 and 4).
FLAG-SMN1, used here as a control, also produced full-
length SMN (Figure 12C, lane 5). Our results confirmed
that mRNAs generated by the eU1-induced activation of
Cr1 from FLAG-SMN1G1C are actively exported from the
nucleus and are translationally competent.
DISCUSSION
SMA is a devastating cause of infant mortality that results
from low SMN. The only approved therapy for SMA re-
lies upon the availability of two or more SMN2 alleles that
could be targeted to elevate the SMN level through splic-
ing correction (70). Here, we report a novel eU1-based ap-
proach aimed at benefiting a broad spectrum of SMA pa-
tients, including those affected by lethal splice site muta-
tions. We began this study in an effort to find a poten-
tial rescue strategy for a severe SMA patient harboring
a pathogenic G-to-C mutation at the first position (G1C)
of SMN1 intron 7. Reproducing the devastating conse-
quences of the G1C mutation, transcripts derived from the
SMN1G1C minigene we generated showed complete skip-
ping of exon 7 (Figure 1). Hence, we used this minigene as
a valuable tool to explore potential therapeutic avenues for
correction of exon 7 splicing. We first asked if skipping of
SMN1G1Cexon 7 could be prevented through promotion of
intron 6 splicing employing engineered U1s (eU1s) target-
ing the G1C-5′ss. We tested a library of eU1s predicted to
formduplexes of varying lengthswith theG1C-5′ss.Most of
these eU1s prevented SMN1G1Cexon 7 skipping; however,
the major splice product was intron 7-retained transcript.
Supporting a direct correlation between the eU1:G1C-5′ss
duplex size and intron 7 retention, eU1s that formed 11 and
6 bp duplexes produced the highest and the lowest levels of
SMN1G1C intron 7-retained transcripts, respectively (Figure
1). The translation stop codon of SMN is located within
exon 7. Hence, the intron 7-retained transcripts will code
for full-length SMN, but will acquire a significantly longer
3′ untranslated region (3′UTR) that might adversely affect
nuclear export and translation. Therefore, we turned our at-
tention towards an alternative strategy of cryptic-splice-site
activation that could generate mRNAs shorter than intron
7-retained transcripts while maintaining the ability to code
for full-length SMN.
An important clue that a cryptic 5′ss immediately down-
stream of the G1C-5′ss could be activated came from the
identification of two novel splice products generated in the
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Figure 11. Effect of simultaneous depletion of hnRNP A1 and A2 on usage of Cr1. (A) Top panel shows a flow chart of the depletion experiment. Bottom
panel shows western blots after transfection with the indicated siRNAs.Minigenes and siRNAs used for transfection are indicated at the top and antibodies
used to probe membranes are indicated on the left of each image. (B) Splicing of endogenous SMN exon 7 in HeLa cells treated with the indicated siRNAs.
Spliced products amplified by RT-PCR were digested with DdeI to distinguish between the transcripts originating from SMN1 and SMN2 (29). The
percentage of SMN2 exon 7 skipping was calculated as in (48). 3′Ex8 represents the cleavage product of DdeI digestion of SMN2 exon 8. (C) Splicing
pattern of transcripts generated by SMN1G1C and SMN1U6G minigenes in HeLa cells treated with the indicated siRNAs. The identity of splice products
is marked on the right of the gel. Quantification of the relative amount of the indicated splicing products is given in the bottom panel as a bar diagram.
Error bars represent standard error. Abbreviations are described in Supplementary Table S1.
Downloaded from https://academic.oup.com/nar/article-abstract/45/21/12214/4158474
by Iowa State University user
on 21 February 2018
Nucleic Acids Research, 2017, Vol. 45, No. 21 12235
Figure 12. Translation of mRNAs generated by an eU1-induced activation of Cr1. (A) Diagrammatic representation of the human FLAG-SMN1 and
FLAG-SMN1G1C expression vectors. Colored boxes represent 3XFLAG tag and exons, lines indicate intronic sequences. eU1s and their annealing sites
within intron 7 are indicated. The G1C-5′ss is indicated by an arrow. Site 2 (Cr1) is underlined. Location of primers used for RT-PCR is indicated.
Abbreviations: E, exon; I, intron; Cr1, cryptic site 1. (B) In vivo splicing pattern of FLAG-SMN1G1Cand FLAG-SMN1 expression vectors in the presence
of eU1s shown in (A). PCR products were resolved on a 5% native gel and visualized by ethidium bromide staining. Sample loading was adjusted to have
comparable band intensity. The identity of the SMN expression vectors and eU1 constructs used is marked at the top of the gel. The identity of splice
products is indicated on the left of the gel. (C) Western blot showing the effect of the indicated eU1 snRNAs on the levels of 3X-FLAG-tagged SMN
protein. The identity of the SMN expression vectors and eU1 constructs is marked at the top of the gel. Antibodies used are indicated on the left. The
identity of SMN protein isoforms is marked on the right. SMN refers to the full-length SMN protein; SMN7, to the truncated isoform that lacks the
sequence encoded by exon 7. Abbreviations: C, control when FLAG-SMN1G1C was transfected without a U1 construct. (D) Model representing the effects
of an ISS-N1-targeting ASO and an eU1-induced activation of Cr1 on the SMN protein production. Exons and introns are indicated by colored boxes
and lines, respectively. ASO is shown as a red bar, eU1 as a blue structure. Positioning of ISS-N1 and stop codons are marked. Location of the wt-5′ss,
G1C-5′ss and cryptic sites (Cr1 and Cr2) are indicated by arrows. C at the first position of intron 7 is marked in red; red crossing signifies that this mutation
renders the native 5′ss of exon 7 inactive. Abbreviations are described in Supplementary Table S1.
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presence of eU1s targeting the G1C-5′ss. These products
included exon 7 extended by 23 and 51 nts due to the ac-
tivation of two novel cryptic 5′ss located in intron 7. We
named them Cr1 and Cr2, respectively (Figure 1). The rel-
atively strong activation of Cr1 was somewhat surprising,
since several existing algorithms scored it as a very weak
5′ss. In search for the strongest cryptic 5′ss that could be ac-
tivated, we employed eU1s that targeted six sites with GU
residues immediately downstream of the G1C-5′ss (Figure
2). While site 1 partially overlapped with the G1C-5′ss, sites
2 and 4 corresponded to Cr1 and Cr2, respectively. All de-
signed eU1s were predicted to form an 11bp duplex with
their respective targets to ensure their efficient recruitment.
Three eU1s that targeted sites 2 (Cr1), 3 and 4 (Cr2) sub-
stantially restored exon 7 inclusion through Cr1 usage. The
remaining three eU1s that targeted intronic sequences up-
streamof site 2 or downstreamof site 4 preventedSMN1G1C
exon 7 skipping by stimulating intron 7 retention. These re-
sults suggested that the redefinition of exon 7 by activation
of Cr1 depends upon annealing of an eU1 within a narrow
sequence stretch spanning from site 2 through site 4. We hy-
pothesize that the recruitment of eU1s within this narrow
sequence stretch is conducive for the spliceosomal assembly
leading to the removal of intron 7. An eU1 that targeted site
5 had the smallest effect on SMN1G1C exon 7 splicing. Site 5
corresponds to a uridine-rich region, deletion of which has
been shown to promote SMN exon 7 skipping (44). Con-
sidering that the site 5-targeting eU1 did not stimulate Cr1
activation nor did it promote intron 7 retention, we hypoth-
esize that a factor(s) interacting with site 5 is critical for the
definition of exon 7 and the removal of the upstream intron
6.
Similar to SMN1G1C transcripts, SMN1G1Uand
SMN1G1Atranscripts also showed the increase in exon
7 inclusion from Cr1 in the presence of eU1 targeting
sites 2, 3 and 4 (Supplementary Figure S5). These results
confirmed that Cr1 activation is not specific for the G1C
context of the mutated 5′ ss of exon 7. In agreement with
a recent report (25), eU1s that targeted sites 1 through 4
promoted robust inclusion of exon 7 through usage of the
wt-5′ss in transcripts derived from the SMN2 minigene
(Figure 2). We also observed small but noticeable activation
of Cr1 in transcripts derived from the SMN2 minigene as
well as from endogenous SMN1 and SMN2 genes in the
presence of eU1s targeting sites 2 (Cr1) and 3 (Figure 2,
Supplementary Figure S4). These results confirmed that
Cr1 usage is regulated by the local context rather than by
the promoter structure or by sequences upstream of exon
6. Interestingly, similar to SMN1G1C the site 5-targeting
eU1 did not promote inclusion of exon 7 in SMN2 tran-
scripts. These results support a hypothesis that a factor(s)
interacting with site 5 is critical for the usage of both the
wt-5′ss and Cr1.
Our results also captured the effect of eU1:Cr1 du-
plex size on the usage of Cr1. For instance, shortening of
eU1:Cr1 duplex size from 11 to 9 bp improved activation of
Cr1 and reduced the levels of intron 7-retained transcripts
of SMN1G1C (Figure 3). While the shortest eU1:Cr1 du-
plex to activate Cr1 was 6 bp-long, not all duplexes of this
length were equally potent in doing so. For the most part,
eU1:Cr1 duplexes of 7- and 8bp-long activated Cr1 with
high efficiency. These results confirmed that SMN1G1C exon
7 inclusion could be rescued by a broad range of eU1:Cr1
duplex sizes. However, no specific rule emerged with re-
spect to the connection between the size of the eU1:Cr1
duplex and the activation of Cr1. Next we asked whether
the Cr1-activating eU1 would also rescue inclusion of exon
7 with an abrogated 3′ss. To answer this question, we cre-
ated the SMNG-1U minigenes carrying a pathogenic G-to-
U mutation (G-1U) at the invariant last position of in-
tron 6. As expected, transcripts derived from SMN1G-1U
or SMN2G-1U undergo complete skipping of exon 7 (Fig-
ure 4). Interestingly, the eU1 that directly targeted Cr1 sig-
nificantly increased exon 7 inclusion by activating the wt-
5′ss and a novel cryptic 3′ss (E7-3′Cr) within exon 7 in both
SMN1G-1U and SMN2G-1U. E7-3′Cr usage reduces the size
of exon 7 from 54 nts to 46 nts. An early study suggested that
∼50 nts are required between the 3′ss and the 5′ss for an
eU1-dependent activation of the upstream 3′ss (71). Con-
sistently, the eU1 that displayed perfect complementarity
with the wt-5′ss of exon 7 was unable to activate the E7-3′Cr
and did not improve exon 7 inclusion in either SMN1G-1Uor
SMN2G-1U transcripts (Figure 4). Interestingly, the site 3-
targeting eU1 caused a small increase in exon 7 inclusion
and only in SMN1G-1Ubut not in SMN2G-1U. This differen-
tial effect could be attributed to aU residue at the sixth posi-
tion in SMN2 exon 7. ThisSMN2-associated C6U is known
to strengthen the terminal stem–loop 1 (TSL1) structure
and/or create a binding site for hnRNP A1/A2 and Sam68
that are the negative regulators of exon 7 splicing [Figure
4, (52,62,63)]. Overall, our results are consistent with the
exon definition model, in which the recruitment of eU1 at
Cr1 appears to drive cross-exon interactions that define the
3′ss of exon 7. Noticeably, eU1s did not trigger activation
of the E7-3′Cr when a pathogenic 7-nt deletion was intro-
duced in the polypyrimidine tract (PPT) of the 3′ss ofSMN1
exon 7 (Figure 5, SMN1ΔPy mutant transcript). Instead,
in the SMN1ΔPy transcripts eU1s targeting sites 2 through
4 promoted exon 7 inclusion through usage of the wt-3′ss
and mostly the wt-5′ss similar to what we observed for the
SMN2 transcripts (Figures 2 and 5). It should be noted,
however, that despite the difference in what 3′ss was se-
lected, our results confirmed yet again that eU1s we used
stimulate the 3′ss recognition, by, for example, assisting in
U2AF65 recruitment to PPT as shown in (72).
We observed a clear difference in the effect of eU1s on
usage of the 5′ss of SMN1 exon 7 mutated at the first in-
tronic position versus 5′ss mutated at a less conserved +6
position of an intron. In particular, contrary to what we
observed in the case of SMN1G1C, eU1 that directly tar-
geted the mutated 5′ss of exon 7 of SMN1U6G activated its
usage accompanied by effective exon inclusion (Figure 5).
We attribute this difference to the presence of some func-
tionality of U6G-5′ss in carrying out the first step of the
splicing reaction, particularly when eU1 is ‘forcefully’ re-
cruited to the U6G-5′ss (Supplementary Tables 2 and 3).
However, the rules seemed to change and differences disap-
pear when the eU1 recruitment site was shifted downstream
of the mutated 5′ss site, since in both minigenes the usage of
Cr1 was activated. In the case of the SMN1 minigene with
a 4-nt deletion from fourth to seventh positions of intron
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7 (SMN1Δ4-5
′ ss), the effect of eU1 overexpression was very
similar to the one we observed for SMN1G1C. For example,
in both minigenes the direct recruitment of the eU1s to the
mutated 5′ss (G1C-5′ss and 4-5′ss) prevented exon 7 skip-
ping but through retention of intron 7 rather that the us-
age of the mutated 5′ss or Cr1 (Figure 5). Furthermore, just
like in SMN1G1C and SMN1U6G, shifting an eU1 recruit-
ment site downstream of the 4-5′ss activated the usage of
Cr1 (Figure 5). Overall, our results are consistent with the
hypothesis that the recruitment of an eU1 within a narrow
sequence stretch spanning from site 2 through site 4 is es-
sential for activation of Cr1.
One of the most surprising findings of our study was the
predominant activation of Cr1 by eU1s that targeted ran-
dom intronic sequences upstream and downstream of Cr1
(Figure 6). None of the eU1 annealing sequences had in-
variant GU-dinucleotides associated with the 5′ss. Our re-
sults refined the sequence range of eU1 annealing for Cr1
activation. In particular, annealing of an eU1 within a∼50-
nt sequence stretch starting from ISS-N1 to site 4 promoted
activation of Cr1. However, for reasons not yet understood,
the effects of different eU1s targeting this sequence stretch
on the activation of Cr1 varied. Our findings are distinct
from a previous study in which deletion of four nucleotides
(GUAA residues) of the U1 snRNP recruitment site within
a cryptic exon of ATM gene promoted usage of this cryp-
tic exon (19). In contrast, Cr1 usage places the annealing
site of eU1-I7R8 within the exonic region and yet this eU1
efficiently promoted exon 7 inclusion through activation of
Cr1 (Figure 6). At the same time, our findings showed a dif-
ferential eU1 effect on splicing when the annealing target
within the exon is altered. For example, compared to eU1-
I7R8, eU1-I7R10 that annealed further upstream within
exon 7 predominantly promoted intron 7 retention (Figure
6). This difference could be attributed to the eU1-I7R10 an-
nealing site that falls outside of the Cr1 activation range
described above. The effect of eU1s targeting random non-
GU sequences was the same in SMN1G1C and SMN1U6G
transcripts. In the case of SMN2, all eU1s, including eU1-
I7R10, produced a strong stimulatory effect on exon 7 in-
clusion mainly through the activation of the wt-5′ss. Taken
together, our findings confirmed that, while Cr1 was acti-
vated by eU1 annealing to a narrow sequence stretch, the
usage of the wt-5′ss was promoted by eU1s annealing to a
broader region.
We discovered that single nucleotide substitutions within
intron 7 strongly activate Cr1 and Cr2. The most interest-
ing observation was that the A23G and A28G substitutions
completely abrogated the usage of the wt-5′ss even in the
context of SMN1 (Figure 7). The effect of the above mu-
tations on activation of Cr1 appeared to be more robust
than the effect caused by targeting Cr1 with an eU1. This
is not surprising considering that a mutation aimed at in-
creasing the strength of a 5′ss in question would produce a
broader effect, including improved recognition of the site by
U1 snRNP, U6 snRNP and possibly other factors involved
in pre-mRNA splicing (23). Interestingly, A23G/A28Gmu-
tations fully restored SMN2 exon 7 inclusion through Cr1
activation even in the context of the abrogated Tra2-ESE
(Figure 7). These results confirmed that the previously de-
scribed ESEs associated with ASF/SF2 and Tra2 are not
required for the activation of Cr1. Further, the first in vivo
selection of the entire exon conducted on SMN exon 7 re-
vealed the stimulatory effect of the non-wt G residue at the
last position of exon 7 (A-1G) for its inclusion (36). Con-
sistently, A-1G substitution was found to obviate the re-
quirement of all known positive elements within exon 7 (36).
Combining A-1G with A23G/A28G mutations resulted in
the activation of both the wt-5′ss and Cr1 with nearly equal
efficiency (Figure 7). It is likely that the same factors are
involved in activation of both the wt-5′ss and Cr.
Consistent with the critical role of ISS-N1 and Cr1 in the
regulation of exon 7 splicing, this regionwas found to be rel-
atively conserved in mammals (Supplementary Figure S7).
Since ISS-N1 andCr1 partially overlap, we wanted to assess
the effect of ISS-N1 on Cr1 usage. In an effort to do so, we
inserted splicing neutral sequences between these two. In-
terestingly, insertion of splicing neutral sequences activated
Cr1 in the context of SMN1G1C and SMN1U6G (Figure 9).
A small but detectable effect of the insertion of splicing neu-
tral sequences on the activation of Cr1 was also observed in
SMN1 but not SMN2. This is not surprising, since SMN1,
SMN1G1C and SMN1U6G all share identical and relatively
strong 3′ss of exon 7. These results suggest that factors inter-
acting with the 3′ss of exon 7 might be important for the ac-
tivation of Cr1. In addition, we have previously shown that
the 5′ss recognition of SMN2 exon 7 is enhanced by TIA1,
a splicing factor that binds to the downstream U-rich clus-
ters (URCs) (44). Insertion of the splicing neutral sequences
moves the URCs away from the 5′ss of SMN2 exon 7 result-
ing in its skipping. The results of site-specific mutagenesis
suggest that URC1 is also important for Cr1 activation (at
least in the context of the SMN1U6G minigene), since abro-
gation of URC1 decreased/abolished the usage of this site,
while strengthening of URC1 improved it (Figure 8).
We observed mixed results with mutagenesis of ISS-N1,
which harbors two putative hnRNP A1/A2 motifs. A12C
mutation that abrogated the first hnRNP A1/A2 motif did
not activate Cr1 (Figure 8), suggesting that this motif is not
involved in the suppression of Cr1. However, it is still possi-
ble that the second hnRNPA1/A2motif contributes to Cr1
usage. Our results of depletion experiments only partially
supported the role of hnRNPA1/A2 in suppression of Cr1.
For instance, depletion of hnRNP A1/A2 activated Cr1 in
the case of SMN1U6G but not in the case of SMN1G1C tran-
scripts (Figure 11). Depletion of hnRNP A1/A2 also acti-
vated Cr2 and E6Cr in the context of SMN1U6G transcripts
(Figure 11). These results are significant because they con-
firm that the levels of endogenous U1 snRNP are fully ca-
pable of activating cryptic splice sites, usage of which we
initially captured employing eU1s that formed very strong
RNA:RNA duplexes with their respective targets. Our re-
sults also confirmed that eU1s that activate Cr1 do not re-
quire the assistance of the endogenous U1 snRNP. This is
based on the observation that an ASO-mediated suppres-
sion of endogenous U1 snRNP barely had any effect on the
eU1-induced activation of Cr1, while eU1-induced usage of
wt-5′ss of SMN2 exon 7 was severely impacted (Figure 10).
These findings underscore thatmechanisms of eU1-induced
usage of thewt-5′ss andCr1 could be different. For instance,
while Cr1 was substantially activated by eU1-MI7-R7 that
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does not sequester the invariantGUdinucleotides at the site
of catalysis, whereas, sequestration of the GU dinucleotides
by endogenous U1 snRNP was critical for the usage of the
wt-5′ss (Figure 10). Future studies will determine the mech-
anism by which the usage of Cr1 is regulated, including par-
ticipating cis-elements and transacting factors.
Finally, we examined the physiological significance of our
findings employing a splicing-coupled translation reporter
assay that detects the FLAG-tagged SMNprotein produced
from transcripts that undergo pre-mRNA splicing, includ-
ing Cr1 activation. Our results confirmed that transcripts
generated by Cr1 activation produce full-length SMN (Fig-
ures 12). To the best of our knowledge, this is the first report
to show the generation of the full-length SMN protein from
SMN1 carrying a pathogenic mutation at the 5′ss of exon 7.
Future studies will determine if the addition of 23 nts of in-
tron 7 to the 3′UTR will have an effect on the stability, traf-
ficking and translation of mRNAs generated by Cr1 activa-
tion. Themechanism of the full-length SMN restoration via
eU1-induced activation of Cr1 is distinct from the action of
an ISS-N1-targeting ASO. The latter is incapable of restor-
ing inclusion of SMN1 exon 7 with pathogenic mutations at
its 5′ss (Figure 12D; Supplementary Figure S9). Hence, the
recently approved antisense drug, nusinersen, based on the
ISS-N1 target may not be a viable option for SMA patients
with these types of mutations. Similar to an ASO-based ap-
proach, an eU1-based approach takes advantage of the en-
dogenous transcript for splicing correction. Employment of
transcripts derived from endogenous gene is likely to main-
tain the physiological levels of the protein. The small size of
an eU1 offers a tremendous advantage for its packaging in
an adeno-associated virus type 9 (AAV9) vector, which has
already shown success in eU1 delivery for the treatment of
a genetic disease (73). However, a mouse model carrying a
mutated 5′ss of SMN1 exon 7 will need to be generated to
test the feasibility of the approach in which eU1s are used.
As per one estimate, about 10% of all human inher-
ited diseases are caused by mutations located within splice
sites (74). The G1C mutation is the deadliest mutation
among them, since it inevitably leads to the complete skip-
ping of an exon. Consistent with this argument, a recent
transcriptome-wide analysis in various tissues did not cap-
ture a single incidence of a functional 5′ss carrying a C
residue at the first position of an intron, although exam-
ples of all other residues at the invariant first and second
positions of several functional introns were recorded (75).
Hence, until this point, rescuing splicing of an exon carrying
a G1C mutation has been an impossible task. In this study,
we have shown an alternative strategy using eU1-mediated
activation of a cryptic splice site to completely neutralize the
consequences of the G1C mutation. This eU1-based strat-
egy is applicable for rescuing splicing defects for a broad
range of mutations at both the 3′ and the 5′ss of exon 7 of
SMN genes. A vast number of studies have demonstrated
the critical role of residues of U1 snRNA in the selection of
the 5′ss of an exon (14,76,78). However, the rules by which
U1 snRNP affects 5′ss selection from a distance have at-
tracted very little attention. Our findings clearly demon-
strate that the U1-snRNP-interacting motifs away from the
5′ss could be utilized for therapeutic purposes. Unlike the
general belief that mutations leading to the generation of
cryptic splice sites cause genetic diseases, this report demon-
strates that the activation of a cryptic splice site employing
an eU1 could lead to the rescue of the complete ORF in a
pathological condition. As the number of genetic diseases
caused by aberrant splicing increases, this work illustrates
the promise of eU1-mediated reprogramming of the bound-
ary of an exon for therapeutic solutions.
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